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• Introduction 
1 INTRODUCTION 
1.1  Lipids and signal transduction 
Lipids are integral structural components of cell membranes, which through their ability to 
form  a  bilayer  produce  a  permeability  barrier  between  extracellular  and  intracellular 
compartments,  a function  essential  for cell  survival.  In  addition,  lipids are  essential  for 
signal  transduction  in  response  to  agonist  stimulation  as  their  hydrolysis  produces 
bioactive  molecules  known  to  trigger  many  downstream  signalling  cascades.  The  first 
evidence  for  such  a  signalling  role  came  in  the  1970s  with  the  discovery  of  the 
phosphoinositide (PI) cycle. Subsequently, many studies have shown that a primary event 
following receptor activation is hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2 ) 
by  PI-phospholipase  C  (PI-PLC),  releasing  the  second  messengers  inositol  1,4,5-
trisphosphate (IP3  )  and diacylglycerol (DG).  IP3 modulates intracellular calcium levels by 
controlling  calcium  channels  at both  the  plasma  membrane and  endoplasmic reticulum 
[Berridge 1987,  Putney & Ribeiro 2000] and  DG  binds to and  activates protein kinase C 
(PKC) [Nishizuka 1995] which initiates a distinct and separate signalling cascade. Further 
studies  have  shown  the  production  of  many  bioactive  lipids  generated  by  receptor-
mediated hydrolysis of glycerophospholipids such as phosphatidic acid (PA) produced by 
a  phospholipase  0  (PLD)  acting  on  phosphatidylcholine  (PC)  [Exton  1997]  or  by  DG 
kinases phosphorylating DG [Topham & Prescott 1999]. Arachidonic acid produced by the 
action  of  a  phospholipase  A2  (PLA2)  is  also  recognised  as  an  important  signalling 
molecule as well  as being the precursor of a diverse group of bioactive compounds, the 
eicosanoids  [Piomelli  1993].  More  recently,  3-phosphoinositides  generated  following 
growth  factor and  G  protein-coupled  receptor  activation  by the  action  of PI  3-kinases 
(PI3Ks)  on  inositol  phospholipids  have  been  recognised  as  important  signalling  lipids 
[Leevers  et  al.  1999].  One  target  of these  lipid  messengers  is  protein  kinase  B,  an 
important  cell  survival  mediator  [Vanhaesebroeck  &  Alessi  2000].  In  addition  to 
glycerolipids,  a  second  class  of lipids  - sphingolipids  - are  now  known  to  act  as  a 
reservoir of signalling molecules [Okazaki et al.  1989, Hannun 1994, Huwiler et al.  2000]. 
Sphingolipids, of which there are more than 300, are found in all eukaryotic cells and  are 
enriched  in  plasma  membranes,  Golgi  membranes  and  Iysosomes  [Merrill  et  al.  1997, 
Huwiler et al. 2000]. In  1986, the sphingolipid derivative sphingosine was shown to inhibit 
PKC [Hannun et al.  1986], suggesting an important role in cell signalling. Introduction 
1.1.1  Sphingolipid metabolism 
Figure 1: Sphingolipid metabolism 
Sphingolipids  are  characterised  by  their  sphingoid  backbone.  In  mammalian  cells, 
sphingosine  is  the  most  common  sphingoid  base,  while  in  yeast  and  plant  cells, 
phytosphingosine is more common (Fig.  2).  Sphingolipid biosynthesis (Fig.  1) starts with 
the  condensation  of serine  and  palmitoyl-CoA forming  3-ketosphingosine which  in  turn 
undergoes  reduction  to  dihydrosphingosine.  A  fatty  acyl  group  is  added  by  an  amide 
linkage to form dihydroceramide, which is converted directly to ceramide, the precursor of 
all  sphingolipids, by the introduction of a trans double bond between carbons 4 and  5 of 
the sphingoid base [Merrill & Jones 1990]. Different head  groups may then be added to 
ceramide  to  form  more  complex  sphingolipids,  the  simplest  of which  is  ceramide-1-
phosphate,  formed  by  ceramide  kinase.  More  complex  head  groups  include  13-
glycosidically-linked  glucose- or galactose-cerebrosides,  the  addition  of a sulfate group 
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Figure 2: Chemical structure of selected sphiugoJipids 
to galactosylceramide yields sulfatides and di-, tri- and tetra-glycosylceramides are known 
as glycosphingolipids. Gangliosides are a subclass of glycosphingolipids identified by the 
presence of sialic acid in the carbohydrate head group [Huwiler et al.  2000]. The addition 
of phosphorylcholine to ceramide, transferred from PC by sphingomyelin synthase, forms 
sphingomyelin [Merrill & Jones 1990]. Lyso-sphingolipids,  N-deacylated derivatives such 
as 1-galactosyl-sphingosine, glucosyl-sphingosine, sphingosine-1-phosphate, sphingosine 
and  Iyso-sphingomyelin  are  also  found.  These  sphingolipids  are  present  at  very  low 
concentrations but may have important signalling effects either as second messengers or 
through their lytic and membrane-destabilising effects [Iwabuchi et al. 2000]. 
1.1.2  The sphingolipid network 
The sphingolipid network is an  ubiquitous signalling system that is conserved from yeast 
to  humans  [Ballou  et al.  1996,  Hannun  1996,  Spiegel  et al.  1996,  Pena  et al.  1997]. 
Ceramide, the central molecule in this network, serves as a second messenger for several 
cellular  functions  ranging  from  proliferation  and  differentiation  to  groWth  arrest  and 
apoptosis  (Fig.  3).  The  manifold  nature  of ceramide  signalling  is  due  to the  fact that 
ceramide is linked to different downstream effectors involving distinct signalling pathways 
depending on cell type. This nature is further closely  asso~iated with activity of enzymes 
that convert ceramide into other metabolites. 
The catabolic pathway for ceramide generation involves the action of sphingomyelinases 
which  hydrolyse  the  phosphodiester  bond  of sphingomyelin  producing  ceramide  and 
phosphocholine  [Kolesnick  1991,  Spiegel  et  al.  1996,  Merrill  et  al.  1997].  There  are 
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several isoforms of sphingomyelinase, distinguished by pH optima and therefore classified 
in acid, neutral and alkaline sphingomyelinases. Both neutral and acid sphingomyelinases 
are  rapidly and  transiently activated  by diverse exogenous stimuli  like  interleukin-1~ (IL 
1~), tumour necrosis factor-a (TNFa), interferon y (IFNy),  UV-light, radiation,  heat shock, 
or oxidative stress, leading to an increase in ceramide levels in a time frame of seconds to 
minutes [Ballou et a/.  1996, Hannun 1996, Spiegel et a/.  1996, Pena et a/.  1997]. Neutral 
sphingomyelinase also showed more prolonged activation [Hannun 1996]. However, until 
now  it remains  unclear which  of the  sphingomyelinases  is  responsible  for the  stress-
induced production of ceramide. 
In  addition,  ceramide  can  be  synthesized  de  novo  by  condensation  of  serine  and 
palmitoyl-CoA as  the  primary step.  This  pathway requires  several  hours to generate  a 
detectable  increase  of  ceramide  [Bose  et  a/.  1995]  Once  generated,  ceramide 
accumulates or is converted into various metabolites (Fig. 3). 
Figure 3: Sphingolipid biology 
1.1.3  The role of ceramide in cell signalling 
The observalion that sphingolipids could  act as bioactive molecules promoted interest in 
the  role  of sphingolipids  and  especially  of ceramide  in  cellular responses.  Due  to  this 
growing  research  ceramide  has  been  found  to  be  involved  in  cellular stress  response 
including apoptosis, growth arrest and differentiation [Riboni et a/.  1997, Perry & Hannun 
1998,  Levade  &  Jaffrezou  1999,  Huwiler  et  a/.  2000]  whereas  several  ceramide  , 
metabolites  are  proposed  to  exert  opposing  biological  effects  such  as  proliferation  • 
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[Gomez-Munoz et al.  1997, Pyne & Pyne, 2000, Uchida et al. 2002] (Fig. 3). However, the 
mechanisms of action are still poorly defined. 
1.1.3.1  Apoptosis 
Programmed cell death, or apoptosis, is an essential process that regulates many aspects 
of normal  and  pathophysiological  development and  homeostasis in  general  [Hale et  al. 
1996,  Nicotera et al.  1999].  Most eukaryotic cells  have the  ability to commit suicide  by 
activating  a suicide programme in  case that they are  no  longer needed or are  seriously 
damaged  or  infected.  Failure  or  suppression  of  apoptosis  may  contribute  to  the 
development of severe diseases such as cancer and  autoimmune diseases. On the other 
hand,  uncontrolled  overshooting  apoptosis  may  aggravate  the  development  and 
symptoms of diseases like neurodegenerative processes or HIV infection. It is  believed 
that  cellular  sensors  exist  that  register  cell  damage  and  can  either  initiate  repair 
processes, or,  if the injury is too severe, can induce apoptosis [Hale et al.  1996, Nicotera 
et al.  1999]. The major biochemical pathways include the activation of caspases and  of 
mitochondria-associated death events leading to the release of cytochrome c. 
A  number  of  studies  support  the  assumed  role  of  ceramide  in  apoptosis.  Several 
cytokines  and  environmental stress factors that initiate  apoptosis,  including  TNFu,  Fas 
ligand,  ionising radiation,  UV-light, heat shock,  and  oxidative stress, appeared to induce 
ceramide generation [Levade & Jaffrezou  1999,  Huwiler et al.  2000],  closely correlating 
with the induction of apoptosis. 
Moreover,  exogenous  cell  permeable  ceramide,  but  not  dihydroceramide  (Fig.  2) 
mimicked the effect of endogenous ceramide to induce apoptosis. 
Furthermore,  it has been  shown in  several cell lines that exogenous ceramide led  to an 
activation of caspase-3 [Mizushima et al.  1996, Kuo et al.  1997, Tepper et al.  1997, Anjum 
et al.  1998, Machleidt et al.  1998, Spinedi et al.  1998, Yoshimura et al.  1998, Lievremont 
et al.  1999, Turnbull et al.  1999] which was supported by studies with caspase-3 inhibitors 
[Gamen  et al.  1996,  Takeda  et al.  1999],  whereas  ceramide  was  not  able  to  activate 
caspase-1  or caspase-8 [Brenner et al.  1998, Tepper et al.  1999]. Thus, it was tempting to 
speculate that ceramide acts downstream of the early initiator caspases (e.g. caspase 8) 
but  upstream  of the executioner caspases  (e.g.  caspase  3).  Moreover,  caspase-3  was 
demonstrated to be an activator of neutral sphingomyelinase [Tokeda et al.  1999] leading 
to an amplification loop resulting in of high amounts of ceramide. 
Studies using mutants of the cytoplasmic domain of the 55kDa TNF receptor showed that 
specific receptor domains were linked to different sphingomyelinases. These observations 
suggested  that  neutral  and  acid  sphingomyelinases  were  activated  through  distinct 
molecular mechanisms. However, acid and neutral sphingomyelinases were both thought 
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to  be  involved  in  signalling  leading  to  programmed  cell  death.  The  acid  enzyme  is 
activated  through  the  death  domain  adaptor protein  system  leading  to  a stimulation  of 
cathepsin D that has been shown to be involved in TNF-induced cell death [Heinrich et al. 
1999], whereas neutral sphingomyelinase was  connected with another receptor domain, 
termed neutral sphingomyelinase activation domain (NSD),  by binding, factor associated 
with  neutral  sphingomyelinase  (FAN),  that  functionally  coupled  this  domain  to  neutral 
sphingomyelinase [Adam-Klages et al.  1996].  Depending on cell type and stimulus, both 
ceramide  generating  enzymes  could  either  act  concurrently  or act separately  in  TNF-
induced apoptotic signalling [Segui et al. 2001]. 
Another pathway involved in the regulation of apoptosis and survival that may be affected 
by ceramide is the PI-3 kinase/AktiBad pathway. This pathway results in phosphorylation 
of the  Bcl-2 family member Bad  and  thereby protects cells from  undergoing  apoptosis. 
Ceramide has been  shown  to  inhibit this  pathway either by downregulating  PI-3 kinase 
activity [Zundel & Giaccia 1998, Zundel et al.  2000] involving caveolin 1 recruitment to PI-
3  kinase-associated  receptor  complex  [Zundel  et al.  2000]  or by preventing  AktlPKB 
activation [Salinas et al.  2000,  Hajduch et al.  2001,  Stratford et al.  2001] either through 
activating  ceramide-activated  protein  phosphatase  (CAPP)  [Salinas  et al.  2000]  or by 
phosphatase-independent events [Rolz et al. 2002]. 
It was further reported that ceramide  may modulate cell  death by dephosphorylation of 
Bcl-2 in HL-60 cells [Ruvolo et al.  1999] losing the protection that was normally sustained 
by phosphorylation. 
In  addition,  ceramide  may interact with the mitochondrial way of apoptosis by triggering 
the release of cytochrome c [Rosse et al.  1998, Ghafourifar et al.  1999]. Moreover, it has 
been shown that ceramide reduced the mitochondrial oxidative phosphorylation [Gudz et 
al.  1997] leading to a disruption of mitochondrial function [Arora et al.  1997]. 
1.1.3.2  Growth arrest 
Growth  and  division  of  proliferating  cells  are  strictly  controlled  processes  that  are 
regulated by a complex interplay of a variety of enzymes within the cell cycle. A prominent 
role  in  the  regulation  of the  cell  cycle  is  exerted  by  cyclins,  cyclin-dependent  kinases 
(Cdks) and  Cdk inhibitors. During normal cell cycling in the G1  phase, an active complex 
of cyclin  D and  Cdk4/Cdk6  phosphorylates  the  retinoblastoma  (Rb)  protein  which  then 
releases  a family of transcription  factors called  E2Fs that induce expression of various 
genes required for cell proliferation. The phosphorylated Rb protein is essential for a cell 
to  enter the  following  S  phase  [Chen  et al.  1989].  This  sequential  activation  of cyclin 
D/Cdks/Rb/E2F  is  again  regulated  by  the  tumour  suppressor  p53  which  induces 
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expression of the Cdk inhibitor p21wAF1/CIP1 [EI Deiry et al.  1993] and thereby prevents Rb 
phosphorylation and progression into the S phase. 
Several studies proposed that ceramide may interact with different points of the cell cycle 
as shown by exogenously applied ceramides causing cell cycle arrest of the G1/S and the 
G2/M transition [Dbaibo et al.  1995,  Rani et al.  1995, Alesse et al.  1998]. Hence, it has 
been speculated  that Rb  was dephosphorylated by ceramide and  thereby the cell  cycle 
could be stopped [Dbaibo et al.  1995, Alesse et al.  1998]. 
Besides, ceramide was able to induce p21wAF1/CIP1 protein levels leading to prevention of 
cyclin-dependent kinase activation and  Rb  phosphorylation [Alesse et al.  1998, Oh et al. 
1998] so that re-entry into the S phase was blocked. 
1.1.3.3  Differentiation 
Differentiation  of  pluripotent  cells  is  a  crucial  step  in  embryogenesis  and  tissue 
development,  especially  the  neuronal  development.  To  investigate  this  kind  of  cell 
response,  undifferentiated cells were very suitable because of their potential to undergo 
differentiation after a certain stimulus.  For example, the promyelocytic leukemia cell line 
HL-60 could  differentiate to either a macrophage-like cell (Le.,  by vitamin  D3  or phorbol 
ester) or a granulocytic cell (Le., by retinoic acid or cAMP). 
Ceramide has been  shown to  be  able to mimic vitamin D3 or TN Fa-induced  monocytic 
differentiation [Okazaki et al.  1989]. Moreover, vitamin D3 itself represented an inducer of 
ceramide formation in  HL-60 cells indicating that vitamin D3 may act as differentiator via 
ceramide or some of its downstream targets, respectively. 
In  other studies retinoic acid  activated neutral sphingomyelinase in  neuroblastoma cells 
leading to  increased  ceramide levels which  were paralleled  with differentiation of these 
cells  detected  by  enhanced  neurite  outgrowth  [Riboni  et  al.  1995].  This  finding  was 
supported. by  exogenously  applied  ceramide  causing  a  comparable  effect  [Harel  & 
Futerman 1993, Riboni et al. 1998]. 
1.1.4  Ceramidases 
The regulating mechanisms that determine the intracellular ceramide level are still poorly 
investigated.  Most studies  have focused  on  the  ceramide-generating  enzymes,  Le.  the 
acid and neutral sphingomyelinases. Based on activity measurements from cell extracts, 
activators of acid and / or neutral sphingomyelinases have been determined and include 
pro-inflammatory cytokines, growth factors and other environmental stress stimuli [Levade 
& Jaffrezou 1999, Huwiler et al.  2000]. However, sphingomyelinases only depict one side 
of the regulation  of ceramide  level.  Therefore,  it is  equally important to understand the 
involvement of ceramide-degrading enzymes, the ceramidases. 
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Ceramidase is an  enzyme that catalyses hydrolysis of the  N-acyl linkage of ceramide to 
produce  sphingosine,  which  subsequently  can  be  phosphorylated  to  sphingosine-1-
phosphate by sphingosine kinase [Merrill et at.  1997]. Sphingosine is not produced by de 
novo synthesis [Michel et at.  1997], and thus the activity of ceramidase is crucial not only 
for switching  off the ceramide-induced  signalling  but also for generation of sphingosine 
and  sphingosine-1-phosphate (Fig.  3).  Ceramidases are classified into three categories: 
acid,  neutral  and  alkaline  enzymes  depending  on  their  pH  optimum.  However,  this 
classification is  not only based on  the pH  value of optimal  enzyme function but also on 
their  primary  genetic  structure.  Furthermore,  the  intracellular  distribution  is  also  quite 
different,  the  acid  enzymes  are  exclusively  present  in  Iysosomes  [Koch  et  at.  1996], 
neutral  enzymes  in  endosome-like  organelles  [Mitsutake  et  at.  2001],  mitochondria  [EI 
Bawab  et  al.  2000]  or at the  plasma  membrane  [Mitsutake  et  at.  2001],  and  alkaline 
enzymes  in  the  endoplasmatic  reticulum  and  the  Golgi  apparatus  [Mao  et  at.  2001], 
respectively.  With  regards to  these differences, the  particular forms of cermidases may 
account for specific physiological roles. 
Furthermore,  the  acid  and  neutral  ceramidases  were  found  to  be  released  by  murine 
endothelial  cells  [Romiti  et  at.  2000a],  although  the  characterisation  of this  secretory 
enzyme still needs to be performed. 
1.1.4.1  Acid ceramidase 
Acid  ceramidase  is  thought  to  be  a  housekeeping  enzyme  to  catabolise  ceramide  in 
Iysosomes and thereby perform the final step of glycosphingolipid catabolism [Bernado et 
at.  1995]. Glycosphingolipids form cell type-specific patterns on the cell surface, which can 
change  with  cell  growth,  differentiation,  viral  transformation,  or oncogenesis  [Hakamori 
1981].  Degradation of glycosphingolipids takes place in the  acidic compartments of the 
cell, namely Iysosomes [Sandhoff & Kolter 1997]. The lysosomal degradation of ceramide 
requires  sphingolipid  activator proteins  (SAP)  as  cofactors  in  vivo,  characterised  as  a 
group of small, heat-stable, enzymatically inactive glycoproteins [FOrst & Sand hoff 1992]. 
Acid  ceramidase  was  purified  from  human  urine  [Bernado et  at.  1995],  and  the  cDNA 
encoding the enzyme was isolated from  human [Koch et at.  1996] and  mouse [Li et at. 
1998]  cDNA  libraries.  Regarding  tissue  specificity,  acid  ceramidase  is  ubiquitously 
expressed whereby kidney shows the highest activity followed by brain. 
Human  acid  ceramidase  is  a  heterodimeric  protein  consisting  of an  unglycosylated  a 
subunit of 13 kDa and a N-glycosylated  ~ subunit of 40 kDa.  Both subunits arise from a 
single glycosylated precursor protein of about 55 kDa which is processed into the mature 
enzyme.  Endoglycosidase  F  treatment  results  in  a  reduced  molecular  mass  for  the 
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precursor from 55 kDa to 40 kDa  and the  ~ subunit from 40 kDa to 29 kDa whereas the 
size of the a subunit remains unchanged [Koch et a/.  1996]. 
A  deficiency  of the  enzyme  causes  the  so-called  Farber  disease  (FD)  which  is  an 
autosomal  recessive  disorder that  manifests  during  the  first few months after birth.  In 
thelSe  patients  ceramide  accumulates  in  the  Iysosomes  of most tissues  [Moser 1995], 
leading  to  painful  swelling  of the  joints  and  tendons,  pulmonary  insufficiency,  and  a 
shortened  life-span.  The  clinical  diagnosis  of  FD  is  usually  confirmed  by  biochemical 
methods,  including  the  determination  of lysosomal ceramide  accumulation  and  / or the 
deficiency of AC  activity. To date,  seven FD  subtypes have been described with varying 
degrees of clinical outcome. Six of which are believed to be primarily caused by mutations 
in  the  acid  ceramidase gene.  Farber disease type 7 is the  result of a complete  lack of 
sphingolipid activator proteins (SAPs) due to a mutation in the initiation codon of the SAP 
precursor  protein  prosaposin  and  is  also  known  as  sphingolipid  activator  protein 
deficiency. This deficiency not only affects the degradation of ceramide by AC but also the 
degradation of other glycosphingolipis such as glucosylceramide and  galactosylceramide 
by glucocerebrosidase and galactocerebrosidase, respectively [Moser 1995]. 
Murine acid ceramidase amino acid sequence is highly homologous to the human protein, 
with  an  overall  amino acid  identity of 90%.  Five of the  six human  N-glycosylation sites 
were  identical  in  the  mouse,  as  well  as  the  cleavage  site  that  generates  the  human 
subunits [Li et al.  1998]. 
In vivo, acid ceramidase activity could be stimulated by  IL-1~ in rat hepatocytes [Nikolova-
Karakashian et al.  1997]  and  this  induction appeared  to  be  tyrosine  kinase-dependent, 
whereas TNFa was able to activate acid ceramidase in rat renal mesangial cells [Huwiler 
et al: 1999b]. 
1.1.4.2  Neutral ceramidase 
Neutral  ceramidase  changes  the  balance  of ceramide  I  sphingosine  I  sphingosine-1-
phosphate in response to various stimuli including cytokines and growth factors [Coroneos 
et a/.  1995,  Nikolova-Karakashian  et al.  1997,  Huwiler  et  al.  1999b],  and  due  to  its 
localisation it is an  attractive candidate for regulation of sphingolipid-mediated signalling. 
However, the biological function of the enzyme still needs to be investigated. 
Molecular  cloning  of neutral  ceramidases  has  been  performed  in  rat  [Mitsutake  et a/. 
2001],  mouse  [Tani  et al.  2000],  human  [EI  Bawab  et a/.  2000],  bacteria  [Okino  et al. 
1999], and  drosophila melanogaster [Yoshimura et al.  2002]. The genetic information of 
the  neutral  ceramidase  gene  family  was  clearly  distinguished  from  that  of  acid 
ceramidase. In contrast to the acid enzymes, the neutral ceramidases are composed of a 
single polypeptide of 70 - 110 kDa. 
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The  rat  enzyme was  characterised  as  a 112 kDa  membrane-bound  ceramidase  having 
nine  putative  N-glycosylation  sites  and  one  possible  transmembrane  domain.  By 
treatment with  tunicamycin,  a known  inhibitor of N-linked  glycosylation,  the  protein was 
converted  to  an  unglycosylated  87  kDa form  collaterally with loss of activity. In  addition, 
rat neutral ceramidase possesses eight putative casein kinase II  and nine protein kinase 
C  phosphorylation  sites.  Northern  blot  analysis  indicated  high  expression  of the  rat 
enzyme in heart, brain and kidney which was paralleled with enzyme activity [Mitsutake et 
al.2001]. 
The  rat  neutral  ceramidase  amino  acid  sequence  was  found  to  be  homologous  to  the 
sequence found for neutral ceramidase isolated from mouse liver and from human brain. 
92%  and 76% identity were recognised, respectively. Therefore, by analysis of the protein 
sequence, the enzymes showed similar pattern of characteristic sites. 
The  murine  neutral  ceramidase  protein  also  had  several  putative  post-translational 
phosphorylation motifs, one tyrosine specific kinase, nine casein kinase II, and ten protein 
kinase C phosphorylation sites. In addition, nine N-myristoyfation sites were found  in the 
sequence [Tani et al. 2000]. 
The  human  neutral ceramidase protein  sequence revealed  a similar pattern of potential 
post-translational modification sites such as N-myristoylation and N-glycosylation, protein 
kinase  C,  cAMP-dependent  protein  kinase,  and  casein  kinase  II  motifs.  The  major 
difference  concerns  the  localisation  within  the  cell.  The  human  sequence  showed  a 
potential  mitochondrial  targeting  region  and  the  protein  was  exclusively  localised  to 
mitochondria in  HEK 293  and  MCF7 cells when  overexpressed  as  a fusion  protein  with 
green fluorescent protein (GFP) [EI Bawab et al. 2000]. 
The molecular masses are 94 kDa for the murine and 90 kDa for the human enzyme. 
Furthermore,  neutral  ceramidase  was  identified  in  Pseudomonas  aeruginosa  and 
Mycobacterium  tuberculosis  whereas  sequence  homology  to  neutral  ceramidase  was 
found  in  hypothetical  proteins  encoded  in  Arabidopsis  thaliana  and  Dictyostelium 
discoideum [Okino et al.  1999]. 
Recently,  a secretory  neutral  ceramidase  of Drosophila  melanogaster was  cloned  and 
characterised [Yoshimura et al. 2002]. Again, this ceramidase exhibited marked sequence 
identity to  other  neutral  ceramidases:  33.2%  for  Pseudomonas  aeruginosa,  28.6%  for 
Mycobacterium  tuberculosis,  44.5%  for  mouse,  44.7%  for  rat,  and  43.5%  for  human, 
respectively. Typically this enzyme was secreted through the classical pathway involving 
the endoplasmatic reticulum and the Golgi compartment. 
Neutral ceramidase has been shown to be regulated by cytokines [Nikolova-Karakashian 
et al.  1997,  Huwiler et al.  1999b].  Furthermore,  bacterial  ceramidase  was  activated  by 
anionic  glycerophospholipids  [Kita  et  al.  2002]  indicating  a  possible  involvement  of 
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ceramide  hydrolysis  in  atopic  skin  by  the  ceramidase  of  Pseudomonas  aeruginosa. 
Although the etiologic factors in atopic dermatitis have yet to be fully elucidated, dry and 
barrier-disrupted skin is a distinctive feature of this disease which could  be evoked by a 
decrease of ceramide in the stratum corneum [Imokawa et al.  1991]. In this context, Okino 
et al.  [1998]  suggested  that  the  activity  of bacterial  ceramidases  was  related  to  the 
decrease of ceramide in atopic dermatitis. 
1.1.4.3 Alkaline ceramidase 
The 30 kOa alkaline ceramidase, so far now only cloned from yeast [Mao et al.  2000] and 
human  [Mao  et  al.  2001],  efficiently  hydrolyses  phytoceramide,  which  is  resistant  to 
hydrolysis by acid and neutral enzymes. Phytoceramide is characterised by introduction of 
a hydroxyl  group  in  position  4  of the  sphingoid  base  and  is  a  constituent  of complex 
sphingolipids  in  lower  eukaryotes  such  as  Saccharomyces  cerevisiae.  However,  its 
existence has also been shown in many mammalian tissues. 
The  alkaline  ceramidase  did  not  share  any  sequence  homology  with  the  two  other 
described  types  of ceramidases,  although  they  catalyse  identical  cleavage  reactions, 
however,  with  differences in  substrate specificity,  pH  optimum,  and  cellular localisation. 
This enzyme had a pH optimum of 9.5, was activated by calcium and inhibited by zinc and 
sphingosine [Mao et al. 2001]. 
In  addition,  an  alkaline  membrane-associated  ceramidase  which  was  not  further 
characterised has been found to be regulated by growth factors, apparently via a tyrosine 
kinase phosphorylation mechanism [Coroneos et al.  1995]. 
1.2  The mesangial cell 
The  glomerulus  is  built  up  by four cell  types:  endothelial  cells  outlining  the  glomerular 
capillaries, mesangial cells functioning as pericytes adjacent to the glomerular capillaries, 
visceral  glomerular  epithelial  cells,  also  named  podocytes,  attached  to  the  glomerular 
basement membrane, and parietal glomerular epithelial cells covering the inner surface of 
Bowman's  capsule  [Remuzzi  &  Bertami  1998].  Among  these  cell  types  glomerular 
mesangial cells are critically involved during various types of glomerular injury [Sterzel et 
al.  1992,  Floege et al.  1994, Pfeilschifter 1994, Schlondorff 1996]. As active part of the 
inflammatory response to glomerular injury, mesangial cells cross-communicate with the 
invading  immune  cells  such  as  neutrophils  or  macrophages  resulting  in  increased 
production of mediators and extracellular matrix and increased mesangial cell proliferation 
[Sterzel et al.  1992,  Floege et al.  1994,  Pfeilschifter 1994, Schlondorff 1996]. Quiescent 
mesangial  cells  do  not produce any pro-inflammatory mediator constitutively.  However, 
regarding  injurious  mechanisms  that  are  associated  with  the  invasion  of productive 
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immune cells,  mesangial cells become self-competent to synthesize bioactive molecules 
like eicosanoids, nitric oxide, growth factors and inflammatory cytokines. This interplay of 
mediators  may end  in  repair of damage, if properly controlled.  Otherwise, the scenario 
leads to connective tissue accumulation and irreversible alteration in glomerular structure. 
These processes have been shown to impair glomerular filtration and may finally result in 
sclerosis and renal failure [Pfeilschifter et al. 1993, Pfeilschifter 1994]. 
Due to this critical involvement of mesangial cells in  glomerular response to injury much 
effort has been made to analyse mesangial cell function in normal conditions as well as in 
glomerular diseases. To study the role of mesangial cells during progression of  glomerular 
diseases, cell culture was extensively used over the last years. 
1.3  Aim ofthis thesis 
In  the  past years  it  has  become  clear that  sphingolipids  and  in  particular the  central 
molecule ceramide act as key compounds in the regulation of cell homeostasis particularly 
with respect to cell differentiation, growth arrest and apoptosis [Riboni et al. 1997, Perry & 
Hannun 1998, Levade & Jaffrezou 1999, Huwiler et al. 2000]. Therefore, the enzymes of 
the sphingolipid network are important players of cell signalling in general. 
This  thesis  focuses  on  the  regulation  of ceramidases  which  are  important  ceramide-
metabolising  enzymes,  in  renal  mesangial  cells.  Among  these  I focused  on  the neutral 
enzyme  which,  due  to  its  intracellular  localisation,  is  considered  to  critically  regulate 
ceramide action. 
Particularly,  I wanted to analyse the  involvement of neutral ceramidase in  cell signalling 
and  its role  in  cellular stress response.  Moreover,  I assumed that ceramide metabolism 
may have important consequences for the balance between cell death and survival. 
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2.1  Materials 
2.1.1  Chemicals 
Acrylamide I bisacrylamide-solutions 
Actinomycin D 
Agar 
Agarose 
Ammoniumpersulfate 
Ampicillin 
Angiotensin II 
Aprotinin 
[r-32PjATP 
Bovine serum albumin, fally acid free 
Bovine serum albumin, fraction V 
5-Bromo4-Chloro-3-indolyl-~-D·galactoside 
Cell culture media 
['4C]ceramide 
CGP41251 
clasto-Lactacyslin ~-Lactone 
Coomassie-Brillant-Blue G250 
[a_32PjCTP 
Cycloheximide 
DETA-NONOate 
Diethylpyrocarbonate 
Dimethylformamide 
Dithiothreitol 
Ethidium bromide 
EDTA 
EGTA 
Fetal calf serum 
G418 
Glycine 
Guanidinium thiocyanate 
Hydroxylammoniumchloride 
Insulin-Transferrin-Sodium Selenite Supplement 
Interleukin-1~ 
Isopropylthiogalactopyranoside 
Leupeptin 
Lipofectamine 
L-N-monomethyl-arginine 
~-Mercaptoethanol 
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Roth, Karlsruhe 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Gibco Life Technologies, Karlsruhe 
Biozym, Oldendorf 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Sigma Aldrich Fine Chemicals, Deisenhofen 
BACHEM, Biochemica, Heidelberg 
Roche Biochemicals, Mannheim 
Amersham Pharmacia, Freiburg 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Roth, Karlsruhe 
Gibco Life Technologies, Karlsruhe 
ICN Biomedicals, Eschwege 
Novartis Pharma, Basel 
Calbiochem, Schwalbach 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Amersham Pharmacia, Freiburg 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Alexis, Uiufelingen, Switzerland 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Roth, Karlsruhe 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Gibco Life Technologies, Karlsruhe 
Gibco Life Technologies, Karlsruhe 
Merck, Darmstadt 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Merck, Darmstadt 
Roche Biochemicals, Mannheim 
Novartis Pharma, Basel 
Roth, Karlsruhe 
Roche Biochemicals, Mannheim 
Gibco Life Technologies, Karlsruhe 
Calbiochem, Schwalbach 
Sigma Aldrich Fine Chemicals, Deisenhofen 
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• [35Sjmethionine- and [35Sjcysteine pro mix 
MitoTracker® Orange CMTMRos 
Molecular weight markers (DNA) 
Molecular weight markers (protein) 
Myelin basic protein 
Nucleotide triphosphates 
Oligonucleotides 
[32Pjorthophosphate 
PDGF-BB 
Pepstatin A 
Peptone 140 
Phenol 
Phenylmethylsulfonyl fluoride 
Ponceau S 
Protein A-sepharose 4B CL 
Ro 318220 
y-S-ATP 
[14C]serine 
Skim milk (non fat) 
Sodiumlaurylsarcosyl 
Spermine 
Spermine-NONOate 
Sphingomyelin 
[14C]sphingomyelin 
Tetramethylelhylendiamine 
12-0-tetradecanoyl-phorbol-13-acetate 
TNF-a 
Triton X-100 
Tween 20 
U0126 
Yeast extract 
Materials and Methods 
Amersham Pharmacia, Freiburg 
MoBiTec, GiiUingen 
MBI Fermentas, SI. Leon-Rot 
Amersham Pharmacia, Braunschweig 
Sigma Aldrich Fine Chemicals, Deisenhofen 
PE Biosystems, Weiterstadt 
Roth, Karlsruhe; Gibco Life Technologies, Karlsruhe 
Amersham Pharmacia, Freiburg 
Hofmann La Roche, Basel 
Roche Biochemicals, Mannheim 
Gibco Life Technologies, Karlsruhe 
Roth, Karlsruhe 
Roche Biochemicals, Mannheim 
Serva, Heidelberg 
Amersham Pharmacia, Freiburg 
Calbiochem, Schwalbach 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Amersham Pharmacia, Freiburg 
Fluka, Deisenhofen 
Serva, Heidelberg 
Calbiochem, Schwalbach 
Alexis, Ulufelingen, Switzerland 
Calbiochem, Schwalbach 
Amersham Pharmacia, Freiburg 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Calbiochem, Schwalbach 
Knoll, Ludwigshafen 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Sigma Aldrich Fine Chemicals, Deisenhofen 
Calbiochem, Schwalbach 
Gibco Life Technologies, Karlsruhe 
Acetone, chloroform, ethanol, ether, methanol, isopropyl alcohol, acids and Iyes were from 
the central store of the university hospital Frankfurt. All other, not special listed solvents 
and salts were supplied from Merck (Darmstadt), Roth (Karlsruhe) or Sigma Biochemicals 
(Deisenhoferi). 
2.1.2  Antibodies and antisera 
Anti-acid ceramidase (rabbit, polyclonal) 
Anti-~-actin (goat, monoclonal) 
Anti-green fluorescent protein (mouse, monoclonal) 
Anti-neutral ceramidase (rabbit, polyclonal) 
Anti-ubiquitin (rabbit, polyclonal) 
Anit-GM130 (mouse, monoclonal) 
kindly provided by K. Sandhoff, Bonn 
Santa Cruz Biotechnologies, Heidelberg 
Roche Biochemicals, Mannheim 
Eurogentec, Belgium 
Calbiochem, Schwalbach 
Transduction Laboratories, Kentucky, USA 
14 Anti-goat IgG (horseradish-peroxidase coupled) 
Anti-mouse IgG (horseradish-peroxidase coupled) 
Anti-rabbit IgG (horseradish-peroxidase coupled) 
Anti-mouse IgG (FluoroLink™ Cy™3 labelled) 
Anti-rabbit IgG (Alexa  TM  488) 
2.1.3  Enzymes 
Pfu-DNA polymerase 
Recombinant Protein Kinase C IX,  0, E,  ~ 
Restriction enzymes 
Reverse transcriptase 
RNase A 
T4-DNA ligase 
Taq-DNA polymerase 
2.1.4  Plasm ids 
pBluescript II KS (+) 
pAP3neo vector 
PEGFP-Nl 
2.1.5  Eukaryotic cell lines 
HEK293 
mMC, C57/BI6 
mMC, MAPKAPK-2 -1-
rMC, Bl 
2.1.6  Bacterial strains 
E. coli XL-l blue 
2.1.7  Buffers 
PBS-buffer 10 fold 
TAE-buffer 10 fold 
TBE-buffer 10 fold 
SSC-buffer 20 fold 
Materials and Methods 
Amersham Pharmacia, Freiburg 
Amersham Pharmacia, Freiburg 
Amersham Pharmacia, Freiburg 
Amersham Pharmacia, Freiburg 
Molecular Probes Europe, Leiden, Netherlands 
5tratagene, Heidelberg 
kindly provided  by D.  Fabbro,  Novartis Pharma  Inc., 
Basel 
MBI-Fermentas, 51. Leon-Rot 
MBI-Fermentas, 51.  Leon-Rot 
QIAGEN Inc., Hilden 
Roche Biochemicals, Mannheim 
MBI-Fermentas, 51.  Leon-Rot 
5tratagene, Heidelberg 
kindly provided by M. Ito, Fukuoka 
Cion tech Labotories, Heidelberg 
kindly provided by H. Radeke, Frankfurt 
preparation of primary cells from mouse kidney by A. 
Huwiler, Frankfurt 
k.o.  mice  kindly  provided  by  M.  Gaestel,  Halle, 
preparation of primary cells from mouse kidney by A. 
Huwiler, Frankfurt 
preparation  of primary  cells  from  rat  kidney  by  J. 
Pfeilschifter, Frankfurt 
5tratagene, Heidelberg 
1.5  M  NaCI,  30  mM  KCI,  15  mM  KH2P04,  60  mM 
Na2HP04 
400 mM Tris acetate, 10 mM EDTA 
900 mM Tris borate, 20 mM EDTA 
3 M NaCI, 300 mM Na2Citrat 
All buffers were prepared with highly purified water from a MiIIi-Q-system (Millipore). 
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2.2  Cell culture 
All  cell  lines  were  cultured  at  37°C  in  a  humidified  atmosphere  containing  5%  CO2 
(Heraeus BBD 6220 incubator). For sub cultivation, cells were washed once in phosphate 
buffered  saline  (PBS),  subsequently  trypsinised  (Trypsin,  EDTA)  and  diluted  in  an 
appropriate ratio (1:3 for mouse mesangial cells,  1:4 for rat mesangial cells and  1:10 for 
HEK  293  cells).  For  long-term  storage,  the  cells  were  treated  as  fOllOWS:  after 
trypsinisation,  cells  were  pelleted  (5  min  at  400  x  g,  Heraeus  Megafuge  1.0,  rotor 
75750F), diluted in  freezing medium  (growth  medium with  20%  FCS  supplemented with 
10% DMSO) and stored in cryotubes (Nunc). The cryotubes were cooled down slowly and 
finally stored in liquid nitrogen. 
2.2.1  Culture and stimulation of mesangial cells 
Rat mesangial cells were grown in Roswell Park Memorial Institute 1640 medium (RPMI) 
supplemented  with  10%  FCS,  the  antibiotics  penicillin  (100  U/ml)  I  streptomycin  (100 
Ilg/ml),  insulin  (5  Ilg/ml),  transferrin  (5  Ilg/ml),  sodium  selenite  (5  ng/ml)  and  10  mM 
HEPES, whereas mouse mesangial cells were grown with  15% FCS,  ~-mercaptoethanol 
and one fold non-essential amino acid solution in addition. 
For induction experiments, cells were grown to confluency and rendered  quiescent by 24 
h incubation  in  serum-free  Dulbecco's  Modified  Eagle's  Media  (DMEM)  including  fatty 
acid-free  BSA  (0.1  mg/ml).  Cells were  then  incubated  for varying time periods  in  fresh 
DMEM  including  fatty  acid-free  BSA  (0.1  mg/ml)  containing  the  factors  or reagents  of 
interest. 
2.2.2  Culture and transfection of HEK 293 cells 
HEK 293  cells  were  grown  in  DMEM  supplemented  with  10%  FCS  and  the  antibiotics 
penicillin (100 U/ml) I streptomycin (100 Ilg/ml). 
For transfection experiments 2x10
5 cells I 3.5 cm dish were plated so that they were 50-
80%  confluent  on  the  day  of  transfection.  The  DNA  of  interest  was  diluted  into 
unsupplemented DMEM and incubated at room temperature for 15 minutes. At the same 
time the lipofectamine reagent was also diluted  in  DMEM  without serum and  antibiotics. 
Thereafter the DNA and  lipofectamine were  combined  and  incubated  for 15  minutes  at 
room temperature. While complexes were forming the complete medium on the cells was 
replaced with unsupplemented DMEM. Then the complexes were added and incubated at 
37°C at 5%  CO2 for at least 3 hours. After this incubation complete medium was given to 
bring  the final  concentration  of serum to that of normal  growth medium.  One day after 
transfection  the  medium  containing  the  complexes  was  replaced  with  fresh  complete 
medium. After reaching confluency the cells were either harvested or passaged into fresh 
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culture medium for stable transfection.  For this purpose,  two days after transfection the 
appropriate  antibiotic was  added  to select for expression  of the transfected  antibiotic-
resistance gene. 
2.3  Bacterial culture 
The E.  coli strain XL 1-blue (Stratagene) was used for amplification of plasmid DNA. The 
bacteria were grown in  liquid LB  (Lauria-Bertani) medium  (1 % bacto-tryptone wlv, 0.5% 
bacto-yeast-extract w/v  and  1  % NaCI wlv).  For selection,  the media contained ampicillin 
(50  IJg/ml).  Agar plates were  generated  with  LB-ampicillin  medium  supplemented  with 
agar (15 gIl).  For long-term preservation of transformed bacteria (2.3.2), cells were mixed 
with 30% sterile glycerol v/v and stored at -80°C. 
2.3.1  Competent bacteria 
To  yield  high  transformation  efficiencies  from  plasmid  DNA  in  bacteria,  cells  were 
chemically pretreated. For this purpose, 100 ml LB-medium was inoculated with 200 IJI of 
an overnight bacterial culture and grown at 37°C until the suspension reached an optical 
density of 0.5 (00600 nm).  Bacterial cells were pelleted by centrifugation (15 min, 5000 x g, 
4·C; Heraeus Megafuge 1.0, rotor 7570F) and subsequently resuspended in 100 ml of the 
following salt solution: 100 mM RbCI, 50 mM MnCb, 10 mM CaCI2, 30 mM KOAc and 15% 
glycerol  vlv.  The  suspension  was  mixed  and  incubated  on  ice  for  45  min  before 
recentrifugation at 15 min, 5000 x g, 4°C). The pellet was gently resuspended in 9 ml of a 
second  salt solution (10 mM RbCI,  75 mM CaCb,  10 mM MOPS and  15% glycerol v/v) 
and  incubated  on  ice  for additional  15 min.  Aliquots of competent bacteria  were  snap 
frozen in liquid nitrogen and stored at -80·C. 
2.3.2  Transformation 
200 IJI  of a competent bacteria suspension (2.3.1) were thawed on  ice and 20  IJI  of the 
ligation reaction (2.4.7.2) were added. The bacteria I DNA mixture was incubated for 30 
min followed by 3 min at 42°C. The bacteria were chilled on  ice again for 2 min, before 
200 IJI  of LB-medium was added. For initial expression of the plasmid encoded ampicillin 
resistance, bacteria were incubated for 45 min at 37°C with 180 rpm on a circular shaker 
(Unitron Infors AG, Bottmingen, Switzerland). Subsequently, 100 IJI  of this transformation 
solution was plated on ampicillin containing agar plates. To enable a blue/white screening 
for recombinant clones, the agar plate was supplemented with  100 IJI  X-Gal (2% w/v  in 
dimethylformamide  (OMF»  and  40  IJI  isopropylthiogalactopyranoside  (IPTG)  (0.1  M  in 
distilled water). The plates were incubated overnight at 37°C. 
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2.4  Nucleic acid techniques 
2.4.1  Preparation of plasmid DNA 
Plasm ids were routinely isolated from bacteria cultures using a modified protocol originally 
described  by  Birnboim  and  Doly  [1979].  3  ml  of medium  containing  the  appropriate 
antibiotic(s) were inoculated with a single bacterial colony from a selective agar plate and 
incubated  overnight  by  vigorous  shaking  at 3rC. 1.5  ml  of the  cell-suspension  were 
centrifuged for 2 min at 7000x g,  and  the  medium was  removed  carefully by aspiration. 
The  bacterial  pellet  was  resuspended  in  100  1-11  of solution  I (50  mM  glucose,  25  mM 
Tris/HCI pH  8.0,  10 mM EDTA). Subsequently, 200  1-11  of freshly prepared solution II (200 
mM  NaOH,  1%  SDS  w/v)  were  added  to  the  dispersed  bacteria,  mixed  five  times  by 
inverting the tubes and stored on ice for exactly five minutes. This step lyses the bacterial 
cells and  denatures the DNA.  The lysate was neutralised by 150  1-11  3 M acidic potassium 
buffer pH  5.5  (solution  III),  and  stored  on  ice  for  10  min.  The  high  salt concentration 
causes SDS to precipitate, and the denatured proteins, cellular debris and  chromosomal 
DNA  become  trapped  by  salt-detergent  complexes.  Plasmid  DNA,  being  smaller  and 
covalently closed,  renatures correctly and  remains in  solution. The tube was centrifuged 
for 10 min at 15,000 g and the supernatant containing the plasmids transferred to a fresh 
Eppendorf tube.  A subsequent cleaning  step  using  phenol/chloroform was  performed 
optionally,  as  trace  amount  of phenol  could  disturb  subsequent  enzymatic  reactions 
processing the plasmid DNA. Plasmid DNA was precipitated using 2 volumes of ethanol at 
room  temperature and  a centrifugation step for 10 min  at 15,000 x g.  The pellet was air 
dried for 10-15 min and the DNA was finally dissolved in 15  1-11  of distilled water. 
High  amounts of pure  plasmid  DNA  (up  to  100  I-Ig)  were  prepared  using  the  QIAGEN 
Plasmid Midi Kit as described by the manufacturer. 
2.4.2  RNA isolation from cultured cells 
RNA  isolation  was  performed  according  to  a  protocol  from  Chomczynski  and  Sacchi 
[1987].  Cells were grown and  stimulated  as described above (2.2.1). Cells were washed 
twice  with  PBS  and  last  traces  of  PBS  were  removed  by  a  pipette  tip  attached  to  a 
vacuum  line.  Subsequently,  cells  were  lysed  with  400  1-11  of  GSCN  solution  (50% 
guanidinium thiocyanate w/v,  0.5%  sodium laurylsacrosyl w/v,  15  mM  sodium citrate pH 
7.0  and  0.7%  ~-mercaptoethanol v/v) per 10 cm-plate, scraped with  a rubber policeman 
and the lysate was transferred into an Eppendorf tube. After addition of 40  1-11  2M NaOAc 
pH  4.0,  400  1-11  acidic phenol  (H20-saturated) and  120  1-11  chloroform,  the samples were 
vortexed  vigorously  for  20  sec.  The  vortexed  tubes  were  stored  on  ice,  centrifuged 
(15,000 x g,  10 min) and the aqueous upper phase was transferred into a fresh tube. RNA 
was  precipitated  using  1 ml  of isopropyl  alcohol,  and  isolated  by  a single  centrifugation 
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step  (15,000 x g,  10 min). The RNA pellet was  washed twice with  absolute ethanol,  air 
dried  and  dissolved in  20  jJl  diethylpyrocarbonate (DEPC) treated water.  Following  a 10 
min  incubation  at  65·C,  the  amount  of isolated  RNA  was  quantified  photometrically 
(2.4.3).  3  jJg  of  the  isolated  RNA  was  controlled  for  integrity  by  agarose  gel 
electrophoresis (2.4.4). Finally, RNA was stored at -20·C until use. 
2.4.3  Quantification of nucleic acids 
Concentrations of nucleic acids were determined  photometrically using  a wavelength of 
260 nm (Gene Quant II, Amersham Pharmacia). An optical density (OD) of 1 corresponds 
to approximately 50  jJg/ml double-stranded DNA or 40 jJg/ml for single stranded DNA and 
RNA  [Sambrook  et  al.  1989].  The  ratio  of  the  readings  at  260  nm  and  280  nm 
(OD2so10D28o)  provides an  estimation of the purity of the nucleic acid  preparation. Highly 
pure DNA or RNA are characterised by ratios between 1.8 and 2.0. Low amounts of DNA 
were  estimated  by  agarose  gel  electrophoresis  (2.4.4)  in  comparison  with  a  known 
standard concentration. 
2.4.4  Agarose gel electrophoresis 
Nucleic acids were usually separated by gel electrophoresis using agarose gels. The gel 
concentration  was  dependent  on  the  molecular weight  of the  analysed  nucleic  acids. 
Agarose (Biozym) was dissolved in  1x TAE gel electrophoresis buffer. Ethidium bromide 
was added to a final concentration of 500 ng/jJl.  Ethidium bromide binds to DNA or RNA 
by  intercalation  between  the  bases  and  thus  enables  an  ultraviolet  fluorescence 
illumination of nucleic acids. The DNA I RNA probes were diluted with loading buffer (6x 
loading buffer: 30% glycerol vlv, 0.25%  bromophenolblue wlv,  0.25% xylenecyanole w/v, 
60%  10x TAE buffer v/v)  and  transferred into the appropriate gel wells.  Electrophoresis 
was performed in 1x TAE buffer with a voltage of 5-10 V/cm gel. DNA fragment sizes were 
estimated using molecular weight markers (MBI Fermentas). 
2.4.5  DNA isolation from agarose gels 
The  use  of the  NucleoSpin-DNA-Extraction-kit  (Machery  &  Nagel,  DGren,  Germany) 
enables a pure  extraction  of DNA fragments directly from  agarose gels.  The system is 
based  on  a  silica  matrix,  which  binds  single  and  double-stranded  DNA.  The  DNA 
fragments  of interest were  cut  from  the  gel  with  a  razor blade  and  further  processed 
according to the instructions of the manufacturer. 
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2.4.6.1  Reverse transcription 
Materials and Methods 
The enzyme reverse transcriptase synthesises a complementary DNA strand using RNA 
as  a  template.  This enzymatic  activity  provides  access to  the  generation  of cDNA.  In 
general, eukaryotic mRNAs are characterised by a series of adenine nucleotides at the 3'-
end, the so called poly-(A} tail. Through hybridisation with oligo-(dT} primers, these poly-
(A) sites are ideal start points for the reverse transcriptase enzyme. Additionally, random 
hexamers (50 ng/J.lI) were used as internal enzyme start sites. 
Reverse transcriptase reaction:  RNA 5J.1g 
oligo-(dT) primer 0.5J.1g 
1  x reverse transcriptase buffer 
dNTP-Mix 2 mM 
RNase inhibitor 20 U 
reverse transcriptase 40 U 
2.4.6.2  Polymerase chain reaction (peR) 
This methods enables the in vitro amplification of DNA fragments without time consuming 
cloning  and  identification  steps [Mullis &  Faloona,  1987].  The method  is based  on  the 
availability of heat-stable DNA polymerases which allow multiple denaturing of template 
DNA, annealing of driver sequences (primer) and synthesis of DNA by amplification steps 
within one tube. 
The reaction was performed in a thermocycler (GeneAmp 2400 or 9600, PE Biosystems) 
with the following sequences for PCR: 94°C for 5 min (1  cycle), and 94°C for 1 min, 52°C 
for 1.5 min and 72°C for 1 min  (with variable numbers of cycles) and final extension at 
72°C for 7 min. The number of cycles were: 30 for murine neutral ceramidase, 35 for rat 
neutral  ceramidase  and  25  for glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH). 
Sequences of the primers for analysis of mRNA: mouse neutral ceramidase: forward: TTC 
AAT TCG GGA CTT CAG TGG; reverse: CAA GAA TGT TGG GTG ACA CG; rat neutral 
ceramidase: forward: TGA AGA CGT GTA AAG CCG C;  reverse: TGC GAT AAC GAC 
AGT CAT ATC C;  GAPDH: forward: AAT GCA TCC TGC ACC ACC AA;  reverse:  GTC 
ATT  GAG  AGC  AAT  GCC  AGC.  PCR  products  (length:  793  bp  for  mouse  neutral 
ceramidase,  377 bp for rat neutral ceramidase and 470 bp  for GAPDH) were  run  on  a 
1.5%  agarose  gel  containing  0.5  J.lg/ml  ethidium  bromide.  Identity  of amplicons  were 
confirmed by sequencing using a 310 Genetic Analyser (Perkin Elmer Corp.) The samples 
were stored at 4°C and analysed by agarose gel electrophoresis (2.4.4). 
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10 IJI  5x taq-polymerase buffer 
5 IJI  dNTP-Mix 2 mM 
1 IJI  forward primer 50 IJM 
1 IJI  reverse primer 50 IJM 
1 IJI  taq-polymerase 1 U 
ad 50 IJI  H20 
2.4.7  Manipulation of DNA 
2.4.7.1  Restriction 
Materials and Methods 
Type II endonucleases isolated from bacteria specifically bind palindromic sequences with 
a  subsequent  cleavage  of the  DNA  molecule  at  their  recognition  site.  This  process 
generates  either blunt  end  fragments  or overhanging  cohesive  ends,  which  allow the 
generation of recombinant DNA by enzymatic ligation.  The standard approach for DNA 
digestion  is  subsequently  listed.  After incubation  at the  appropriate temperature,  DNA 
cleavage was checked by agarose gel electrophoresis (2.4.4). 
DNA restriction:  10 IJI  DNA 500 ng 
2.4.7.2  Ligation 
2 IJI  10x restriction buffer 
0.2 IJI  restriction enzyme 3 U 
ad 20 IJI  H20 
Generation of covalent phosphodiester bonds between the 5
0
-phosphate and the 3'-OH of 
DNA fragments is catalysed by T4-DNA ligase. The ligation reaction was performed with 
restricted or PCR amplified DNA. The DNA was separated in  a low-melting agarose gel, 
and the DNA fragment of interest was subsequently cut out. The gel piece was melted at 
68°C  and  added  to the ligation reaction.  The mixture was incubated for at least 5 h at 
room temperature. Afterwards, an aliquot of this reaction was transformed into competent 
bacteria as described in section 2.3.2. 
DNA ligation:  1 IJI  vector DNA (500 ng) 
10 IJI  melted gel I DNA fragment 
41J1  10x ligase buffer 
1 IJI  T4-DNA ligase 1 U 
ad 40 IJI  H2O 
2.4.8  DNA sequencing 
DNA  sequencing  was  performed  using  the  ABI-Prism  310  Genetic  Analyser  (PE 
Biosystems)  based  on  the  dideoxynucleotide  chain  termination  method  [Sanger et  al. 
1977]. In the termination labeling mix, the four dideoxy terminators (ddNTPs) were tagged 
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with different fluorescent dyes. This technique allows the simultaneous sequencing of all 
four  reactions  (A,  C,  G,  T)  in  one  reaction  tube.  The  probes  were  separated 
electrophoretically using a micro capillary. As each dye terminator emits light at a different 
wavelength  when  excited  by  laser  light,  all  four  colors  corresponding  to  the  four 
nucleotides  can  be  detected  and  distinguished  within  a  single  run.  Raw  data  were 
evaluated  by the  Abi  Prism  sequencing  analysis  software  on  a  Power  G3  Macintosh 
computer.  The  sequencing  reaction,  as  listed  below,  was  performed  in  a thermocycler 
(GeneAmp 2400, PE Biosystems) with 25 cycles of the following temperature steps: 96°C 
for  10  sec,  55°C  for  5 sec,  60°C  for  2  min.  For  the  detection  process,  probes  were 
prepared as described by the manufacturer. 
DNA sequencing:  1 III  DNA (250 ng plasmid 150 ng peR derived) 
2 III  sequencing premix 
1 III  primer 10 IlM 
ad 10 III  H20 
2.4.9  Northern blot analysis 
Total RNA was isolated using guanidinium isothiocyanate solution as described (2.4.2). 25 
I.lg of RNA was separated by electrophoresis on  1  % agarose formaldehyd gels. RNA was 
transferred to a nylon membrane by vacuum blotting for 2 h at 55 mbar and cross-linked 
by UV light. Blots were hybridised with a 540  bp  RT-PCR product (forward primer:  CCA 
GTG GGT GM  CAT GAC AG; reverse primer: GAT GTA TGC AGA CAG GGT GT) of the 
rat neutral ceramidase, and  a 1206 bp RT-PCR product (forward primer: GGG GTA CCT 
GGG MG ATG  GGG  GGC CM AGT CTT CTC;  reverse  primer:  GAC TAC TGC TCA 
CCA GCC TAT ACA AG) for the acid ceramidase, which were labeled with a-e
2pj-dCTP 
using the Multiprime DNA Labeling system (Amersham Pharmacia Biotech). Hybridisation 
was carried out at 42°C for 16 h, and the membranes were exposed on a Phosphorimager 
(Fuji).  To  correct  for  variations  in  RNA  amounts,  blots  were  finally  rehybridised  with 
a.-[
32Pj-labeled GAPDH cDNA probe. 
2.5  Protein Techniques 
2.5.1  Preparation of Iysates 
Confluent  mesangial  cells  in  60  mm-diameter dishes were  stimulated  for the  indicated 
time periods in  DMEM containing 0.1  mg/ml of fatty acid-free BSA. To stop the reaction, 
the  medium  was  removed  and  the  cells  washed  with  ice-cold  PBS.  Cells  were  then 
scraped directly into lysis buffer (50 mM  Hepes pH  7.4,  150 mM  NaCI,  1.5 mM  MgCI2,  1 
mM  EDTA,  1  mM  EGTA,  10%  glycerol  v/v,  1%  Triton  X-100  vlv,  20  mM  ~­
glycerophosphate,  50  mM  sodium  fluoride,  1 mM  NaN04, 10 1.l9/mlleupeptin,  10 I.lg/ml 
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aprotinin,  1  IJM  pepstatin  A,  1  mM  phenylmethylsulfonyl  fluoride  (PMSF))  and 
homogenised  by  ten  passes  through  a 26-gauge  needle  fitted  to  a 1 ml  syringe.  The 
homogenate  was  centrifuged  for 10  min  at  15,000 x g  and  the  supernatant  taken  for 
protein determination (2.5.2). Aliquoted samples were stored at -80°C until use. 
2.5.2  Quantification of proteins 
The  amount of protein  in  cellular and  tissue Iysates was  determined  using the  Bio-Rad 
protein assay (Bradford  method).  10  IJI  of the samples diluted in 790  IJI  of distilled water 
were  combined  with  200  IJI  Bio-Rad  5x  dye  solution,  vortexed  and  pi petted  into 
appropriate wells of a 96-well plate. BSA concentrations between 3 - 48 IJg/ml were used 
to  generate  a  standard  curve.  After  10  min  of  incubation,  the  optical  density  was 
measured at a wavelength of 595 nm using a microplate reader (Bio Rad). The absorption 
values were calculated using the Microplate Manager 4.0 software (Bio Rad). 
2.5.3  Trichloracetic acid (TeA) precipitation 
This  method  was  used  to  concentrate  proteins  from  a  defined  volume  of cell  culture 
supernatants for Western blot analysis. 70% trichloroacetic acid (TCA) w/v were added to 
protein extracts in lysis buffer to yield a final concentration of 7%, mixed and incubated for 
30  min on  ice. TCA-precipitated proteins were pelleted by centrifugation (15,000 x g,  30 
min, 4°C). The protein pellet was washed in  200 IJI  of ice-cold acetone, centrifuged for 5 
min at 14,000 g and finally resuspended in  1x SOS buffer (10 mM Tris/HCI pH  7.4, 1 mM 
EOTA,181  mM  OTT,  13%  SOS  w/v,  13.25%  glycerol  vlv,  1.0%  bromphenolblue  m/v). 
After neutralisation (1  IJI of 1 M Tris/HCI pH 8.5 per 50 IJI), the samples were ready to use 
for SOS-PAGE (2.5.6). 
2.5.4  Immunoprecipitation 
Samples of 1 ml volume, containing the indicated amount of proteins, 5% fetal calf serum 
vlv and  1.5  mM  iodoacetamide  in  lysis buffer,  were  incubated  overnight at 4°C  with  a 
polyclonal  antiserum  against the neutral  ceramidase (2.5.7)  at a dilution of 1  :100. Then 
1001.LI  of a 50% slurry of protein A sepharose 4B-CL in  PBS was added and  the mixture 
was  rotated  for  1  h  at  room  temperature.  After  centrifugation  for  5  min  at  3,000  g 
immunocomplexes were washed 3 times with  a low salt buffer (50 mM  Tris-HCI,  pH  7.5, 
150 mM NaCI, 0.2% Triton X100 vlv, 2 mM EOTA, 2 mM EGTA, 0.1% sos w/v), 3 times 
with a high salt buffer (50 mM Tris-HCI pH 7.5, 500 mM NaCI, 0.2% Triton X100 v/v, 2 mM 
EOTA, 2 mM EGTA, 0.1% SOS w/v) and once with 10 mM Tris. Pellets were either boiled 
for  5  min  in  Laemmli  dissociation  buffer  and  subjected  to  SOS-PAGE  (SOS-
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polyacrylamide-gel-electrophoresis)  or  used  for  in  vitro  phosphorylation  experiments 
(2.5.9). 
2.5.5  Metabolic labelling 
Confluent  mesangial  cells  in  100  mm-diameter  dishes  were  washed  with  PBS  and 
incubated in  methionine-free MEM  in  the absence or presence of the stimulators for the 
indicated  time  periods.  For  the  'last  4  h  of  incubation  a  mix  eSS1methionine  and 
[3sS1cysteine was added (140 IlCi/plate). After labelling, cells were washed twice with ice-
cold PBS and scraped directly into 1 ml of lysis buffer and homogenised. The homogenate 
was centrifuged for 10 min at 14,000 g and 5 III of the supernatant were measured in a ~­
counter.  Samples  of 1 ml  volume,  containing  250 x  10
6  cpm  of labelled  proteins  were 
taken  for  immunoprecipitation  (2.5.4)  and  following  SOS-PAGE.  After  fixing  in  25% 
isopropyl  alcohol  v/v,  10%  acetic  acid  v/v,  the  gels  were  dried  and  exposed  on  a 
Phosphoimager  (Fuji).  labelled  bands  corresponding  to  neutral  ceramidase  were 
analysed. 
2.5.6  Western blot analysis 
The Western blot technique represents a sensitive method to detect specific polypeptides 
within  a  complex  mixture  of proteins.  Proteins  are  separated  electrophoretically  and 
transferred to  a membrane, which  is subsequently incubated with  antibodies specific for 
the  protein  of interest.  Finally,  the  bound  antibody  is  recognised  by  a  second  anti-
immunoglobulin antibody that is coupled to horseradish peroxidase which was visualised 
with  enhanced  chemiluminescence  (ECl)  system  (Amersham)  according  to  the 
company's specifications. 
2.5.6.1  SDS gel electrophoresis 
Electrophoretic separation of proteins was carried out in the discontinuous buffer system 
for SOS  polyacrylamide  gels as  originally described  by  laemmli [19701.  100 Ilg of total 
protein were  dissolved in  1x SOS  buffer. After heating for 5 min  at 95°C,  samples were 
loaded on the gel. Subsequently, the gel was run at 80 V for a period of 2-3 hours. 
2.5.6.2  Protein transfer to nitrocellulose membrane 
After gel  electrophoresis,  proteins  were  transferred  onto  a nitrocellulose  membrane  by 
semi-dry electroblotting (Trans-Blot SO, Bio Rad). Prior to use, membrane and filterpapers 
(Whatman  3MM)  were  damped  in  blotting  buffer  (25  mM  Tris,  190  mM  glycin,  20% 
methanol v/v)  as two appropriate pieces of filter. After soaking in blotting buffer, one filter 
was positioned on the anode side of the transfer apparatus. The nitrocellulose membrane 
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was placed directly on the Whatman 3MM paper. The SDS gel containing the separated 
proteins was taken off the glasplates, rinsed shortly in blotting buffer, and placed on  the 
top  of the  membrane.  Finally,  the  gel  was  covered  with  one  additional,  blotting  buffer-
soaked Whatman 3MM  filter.  Air bubbles were squeezed out by a roller apparatus.  The 
upper electrode (cathode) was positioned on the top of the stack and a voltage of 11  volts 
was  applied.  Transfer of proteins  was  carried  out at room  temperature and  terminated 
after 60 min. After blotting, the membrane was checked by Ponceau S (0.2% Ponceau-S 
w/v, 3% TCA w/v) staining for correct electrophoretic transfer and equal loading. 
2.5.6.3  Immunodetection 
The  nitrocellulose membrane was  rinsed  with  distilled  water.  Non-specific binding  sites 
were  blocked  by  shaking  the  membrane  in  blocking  buffer  (50  mM  Tris/HCI  pH  7.4, 
200mM NaCI, 0.2% Triton X-100 w/v, 3%  BSA fraction V w/v, 10% horse serum v/v) for 1 
h at room temperature or overnight at 4°C. The membrane was subsequently exposed to 
antibodies (diluted in blocking buffer in a range of 1  :500 to 1  :2,000) specific for the protein 
of interest. The incubation time varied between 1 h at room temperature, or 15 h at 4°C 
depending on  the  antiserum.  The  blot was  washed  three times for 15 min  in  1x TNTX 
(50mM  Tris/HCI  pH  7.4,  200mM  NaCI,  0.2%  Triton  X-100  v/v)  and  incubated  with  a 
specific secondary antibody coupled to horseradish peroxidase (diluted in blocking buffer 
in  a range  of 1  :5,000 to 1  :20,000) for 1 h at room  temperature.  For visualisation of the 
bands, the enhanced chemiluminescence (ECl) detection kit (Amersham Pharmacia) was 
used according to the instructions of the manufacturer. The membrane was exposed to a 
Hyperfilm  MP  (Amersham  Pharmacia)  and  developed  (Hyperprocessor,  Amersham 
Pharmacia). Developed films were scanned (GS 700 Imaging Densitometer, Bio Rad) and 
analysed using the Molecular Analyst software from Bio Rad. 
2.5.7  Generation and characterisation of a neutral ceramidase antibody 
A  synthetic  peptide  (ENHKDSGNHWFSTC)  based  on  the  N-terminal  sequence  of the 
murine  neutral  ceramidase  (GenBank  TM/EBI  Data  Bank  accession  number AB037111) 
was  synthesised, coupled to keyhole limpet hemocyanin, and  used to immunise rabbits. 
For characterisation of the antibody, Iysates of Il-1~-stimulated (8 h)  rat mesangial cells 
were separated on a MonoQ column coupled to a Biologic FPlC® system. The cell lysate 
was loaded into 25 mM Tris (pH  7.4) and  eluted with a linear gradient of 1 M NaCI in 25 
mM  Tris  (pH  7.4)  at  a  flow  rate  of 2  mllmin.  The  eluted  fractions  were  analysed  by 
Western blotting (2.5.6) and neutral ceramidase activity assay (2.6.1.1). 
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2.5.8  In vivo phosphorylation 
Confluent mesangial cells in  100 mm-diameter dishes were washed twice with  PBS  and 
incubated  for 48  h in  OMEM  containing  fatty  acid  free  0.1  mg  BSAlml.  The cells  were 
washed  three  times  with  phosphate-free  MEM  in  order  to  remove  all  phosphate. 
Afterwards  the  cells  were  metabolically  labelled  for 4  h  with e
2p]orthophosphate  (0.5 
mCi/plate). After labelling, cells were stimulated at 37°C for the indicated time periods with 
various  agents.  To  stop  the  reaction,  the  medium  was  removed  and  the  cells  were 
washed twice with ice-cold buffer containing 20mM Tris/HCI pH 7.5/150 mM NaCI. Cells 
were then  scraped  directly into  1.0  ml  of ice-cold  lysis buffer and  homogenised  by ten 
passes  through  a  26-gauche  needle  fitted  to  a  1  ml  syringe.  The  homogenate  was 
centrifuged  for  15  min  at  15,000  x  g  and  5  (.II  of the  supernatant  was  taken  for 
measurement in a ~-counter. 
The  supernatants  (containing  2.5  x  10
6  cpm  of  labelled  proteins)  were  taken  for 
immunoprecipitation (2.5.4) and following SOS-PAGE as described above (2.5.6.1). After 
fixing in 25% isopropyl alcohol v/v, 10% acetic acid  v/v, the gels were dried and exposed 
to an  Imaging System (Fuji). Phosphorylated bands corresponding to neutral ceramidase 
were analysed. 
2.5.9  In vitro phosphorylation 
Immunocomplexes of interest were tested for direct phosphorylation by using recombinant 
PKC isoenzymes in the presence or absence of calcium. The beads were incubated with 
1 (.Ig of the partially purified enzymes in a total volume of 40 (.II  containing 20 mM Tris/HCI 
pH  7.4,  10 mM MgCI2,  100 (.1M  Na2ATP, 8 (.ICi  [y_
32p]ATP,  1(.1g  phosphatidylserine, 0.1  (.Ig 
diolein,1  (.1M TPA and either 100 (.1M  CaCI2 or 100 (.1M  EOTA for 15 min at 32°C. To show 
PKC isoenzymes' activities 5 (.Ig  of MBP being a well known substrate for PKC [Geiges et 
al.  1997] were included. Thereafter SOS  buffer was added to  stop the reaction  and  the 
samples were separated on SOS-PAGE (8%  acrylamide for neutral ceramidase and 13% 
acrylamide  for  MBP).  Phosphorylated  bands  corresponding  to  neutral  ceramidase  and 
MBP, respectively, were analysed on an Imaging system (Fuji). 
2.5.10 TrypSin digestion 
[
32p]phosphorylated  neutral ceramidase that was  affinity-purified  on  an  anti-ceramidase 
sepharose column was incubated with or without trypsin (100Ilg/ml) in  a final  volume of 
50111  for 3h  at 37°C.  Thereafter,  undigested  samples were  separated  on  a Tris-glycine 
SOS-PAGE (7%  acrylamide gel) and trypsin-digested samples were separated on a Tris-
tricine SOS-PAGE (10-20% acrylamide gel). Phosphorylated bands were analysed on  an 
Imaging system. 
26 Materials and Methods 
2.6  Measurement of cell parameters 
2.6.1  Enzyme activity 
2.6.1.1  Acid and neutral ceramidase activity 
Confluent mesangial cells  in  60mm  dishes were  stimulated  as  described above (2.2.1) 
and homogenised in lysis buffer containing 50 mM sodium acetate pH 4.5, 0.5% Triton X-
100  vlv,  5  mM  MgC12 ,1  mM  EDTA,  5  mM  D-galactonic  acid  ,),-Iactone  for  the  acid 
ceramidase, and 50 mM Tris pH  7.5,  0.5% Triton X-100 vlv, 5 mM  MgC12,1  mM EDTA, 5 
mM  D-galactonic  acid  y-Iactone  for  the  neutral  ceramidase.  Cell  homogenates  were 
centrifuged for 10 min at 15,000 x g, and the supernatant was taken for an in vitro assay. 
100 I-Ig of protein in a total volume of 100 1-11  were incubated for 20 h at 37 ·C with 20 nCi 
of [14Cjceramide.  Thereafter, the reaction was stopped by the addition of 200  1-11  of water, 
and lipid extraction was performed by addition of 2 ml of chloroform / methanol (2: 1, v/v). 
The  lower  phase  was  concentrated  and  lipids  were  resolved  by  TLC  (thin  layer 
chromatography)  using  chloroform  / methanol/ammonia (90:20:0.5,  vlv) as  a solvent. 
Spots corresponding to ceramide (Rf =0.8) and sphingosine (Rf =0.25) were analysed and 
quantified using a Phosphoimager (Fuji). 
2.6.1.2  Acid and neutral sphingomyelinase activity 
For the  sphingomyelinase activity cells were  homogenised  in  lysis buffer containing  50 
mM  sodium  acetate  pH  4.5,  0.5% Triton X-100  vlv, 5 mM  MgCI2, 1 mM  EDTA for the 
acidic sphingomyelinase, and  50 mM Tris pH  7.4, 0.5% Triton X-100 vlv, 5 mM MgCI2, 1 
mM EDTA, 5 mM dithiothreitol for the neutral sphingomyelinase. Cell homogenates were 
centrifuged for 10 min at 15,000 x g,  and the supernatant was taken for an in vitro assay. 
100 I-Ig  of protein in  a total volume of 100  1-11  were incubated for 30 min at 37 ·C with 20 
nCi of [14Cjsphingomyelin. Thereafter, the reaction was stopped by the addition of 200  1-11 
of water and 2 ml of chloroform / methanol (2: 1, v/v) and vortexed for 10 sec. After phase 
separation,  the  radioactivity  in  the  upper  phase  containing  the  phosphocholine  was 
counted in a ~-counter. 
2.6.2  Ceramide formation 
Confluent mesangial cells in 30mm-diameter dishes were labelled for 24 h with [14Cjserine 
(0.2 I-ICi/ml) and stimulated as indicated. Lipids were extracted as follows: the stimulation 
was stopped by withdrawing the stimulating medium and  incubating the cells with  1.0 ml 
ice-cold methanol for 1 h at 4·C. Thereafter, cells were scraped with a rubber policeman 
and  the  lysate was  transferred  into a test tube.  1.6 ml of salt solution  (0.74%  KCI  w/v, 
0.04%  CaCI2 w/v,  0.034%  MgCI2  wlv)  and  2.0  ml  chloroform  were  added  followed  by 
vigorous shaking which resulted in the lipids solved  in  the lower chloroform phase. This 
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separated  lipid  phase  was  transferred  into  a centrifuge  tube.  This  extraction  step  was 
repeated  by  adding  35  IJI  HCI  /  2.0  ml  chloroform  and  a  final  extraction  with  1.0  ml 
chloroform  alone.  The  united  chloroform  phases  were  subsequently concentrated  in  a 
speedvac vacuum  concentrator.  Ceramide  was  resolved  by sequential  one-dimensional 
TLC  using  chloroform  /  methanol/ammonia (65:35:7,5,  v/v)  followed  by  chloroform  / 
methanol/acetic acid  (9:1:1, v/v).  Spots corresponding to ceramide were analysed and 
quantified using a Phosphoimager (Fuji). 
Alternatively, ceramide was quantified by LC/MS/MS spectrometry. The LC unit consisted 
of a Jasco DG 1580-53 degasser, a Jasco  LG-1580-02 ternary gradient unit, a Jasco PU-
1585  pump  and  a  Jasco  AS  1550  autosampler  (Gross-Umstadt,Germany).  The  mass 
spectrometer  consisted  of a  PE  Sciex  API  3000  triple  quadrupol  mass  spectrometer 
(Applied  Biosystems  Langen,  Germany)  equipped  with  a  turbo  ion  spray  interface. 
Nitrogen at high purity was supplied by a Whatman nitrogen generator (Whatman GmbH, 
Goettingen, Germany). 
Chromatographic separation of extracted samples was performed in isocratic mode with a 
Nucleosil  C18  column  (30x2.0  mm  1.0.,  5  IJm  particle  size  and  100  A pore  size, 
Macherey-Nagel, Dueren, Germany). The mobile phase consisted of methanol containing 
2 mM ammonium acetate. The flow rate was set at 0.1  mllmin. The injection volume was 
10  IJI  and  the  running  time  was  4  min.  The  turbo  ion  spray  interface  operated  in  the 
positive ion mode at 5200 V and 200·C and was supplied by an auxiliary gas flow of 4500 
mllmin. The nebuliser gas was set at 1.23 IImin (setting 10), the curtain gas flow was set 
at 1.0811min (setting 9) and the collision gas at 3.7 x10 -6 HPa (3.02 *10
15 molecules/cm
2
) 
(setting 4) . Nitrogen was  used for all  gases. C(16)-ceramide standards and cellular lipid 
extracts were resuspended in  1000 IJI of a 5 mM  ammonium acetate/methanol buffer just 
prior to  MS  analysis.  Standards were analysed at concentrations ranging from 25 nM to 
10 IJM. 
Quantification was performed in multiple reaction monitoring (MRM) (dwell time 200ms) of 
the  protonated  precursor  ion  and  related  product  ions.  The  mass  transition  used  for 
quantification was m/z 538.4-t264.2 (collision energy 33eV).  The mass transitions used 
as  qualifier were  m/z  538.4-t82.1  (collision  energy  77eV)  and  538.4-t252.1  (collision 
energy 3geV). The analytical data were processed by Analyst software (version 1.1). 
2.6.3  Apoptosis 
Apoptotic cell death is characterised by membrane blebbing, chromatin condensation, and 
the  activation  of endonucleases  which  cleave  the  double-stranded  DNA  at  the  most 
accessible  internucleosomal  linker  regions,  finally  generating  mono- and 
oligonucleosomes. As DNA degradation occurs several hours before plasma membrane Materials and Methods 
disassembly,  these  mono- and  oligonucleosomes  are  enriched  in  the  cytoplasm  of 
apoptotic  cells.  The  ELISA  uses  the  determination  of these  soluble  DNA  1 histone 
complexes  as  readout  for  cellular  apoptosis  (Cell  Death  Detection  ELISA,  Roche 
Biochemicals). 
2.7  Confocal microscopy 
Sequential images of the same cell were collected at 1-5 min intervals using LaserSharp 
software through  a Bio-Rad  MRC  1024 confocal  scan  head  mounted  on  a microscope 
(Axioskop FS,  Carl Zeiss, Jena, Germany) with a 603 planapochromat lens. Excitation at 
488 nm was provided by a krypton-argon gas laser with a 522/32 emission filter for green 
fluorescence. 
For  mitochondrial-specific  staining  cells  were  incubated  with  prewarmed  medium 
containing MitoTracker® Orange CMTMRos (250nM) for 30 minutes as suggested by the 
manufacturer. After replacing the loading medium labelled cells were viewed by confocal 
microscopy as described above. 
For  Golgi-specific  staining  with  Anit-GM130  and  for  visualising  uncoupled  neutral 
ceramidase,  respectively,  cells were washed with  PBS  and  fixed  in  methanol containing 
0.02%  EGTA (w/v) at -20·C for at least 1 h.  Thereafter,  cells were rinsed with  PBS and 
incubated with 1  mg/ml  BSA in PBS (PBS/BSA) for 1 h to block nonspecific binding sites. 
Cells were then incubated with a monoclonal GM130-specific antibody (1 :250) or neutral 
ceramidase antibody (1:200) for 1 h. The cells were rinsed with PBS/BSA, incubated for 1 
h with FluoroLink™ Cyl
M3 labelled goat anti-mouse IgG (1 :2000) or Alexa™ 488 goat anti-
rabbit  IgG  (1 :2000)  and  rinsed  with  PBS.  The  labelled  cells  were  viewed  by  confocal 
microscopy using a 63x fold magnification objetive. 
2.8  Statistical analysis 
Statistical analysis was performed by one way analysiS of variance (ANOVA). For multiple 
comparisons  with  the  same  control  group,  the  limit of significance was  divided  by  the 
number of comparisons according to Bonferroni. 
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3.1  Interleukin  1  ~ induces chronic activation and  de-novo synthesis of neutral 
ceramidase in renal mesangial cells 
Introduction 
Inflammatory diseases of the  renal glomerulus are accompanied by enhanced formation 
of the cytokine interleukin-113 (IL-1  13).  The primary source is the activated macrophage, 
but  IL-113  is  also  released  by  many other cell  types after exposure to an  inflammatory 
environment.  Soluble  IL-1  13  is the  predominant form  in  biological fluids,  and  it binds to 
specific  receptors  in  target  tissues.  IL-1  is  an  exemplary  cytokine  that  is  particularly 
important in  the systemic response to inflammation.  It  synergises with  tumour necrosis 
factor-a (TNF-a) for many of its actions, and its synthesis is stimulated, in turn, by TNF-a. 
Furthermore, it is implicated in the pathogenesis of diseases such as rheumatoid arthritis, 
inflammatory bowel disease, septic shock, and several autoimmune reactions. 
In  this  part of the  thesis,  the  effect of the  IL-113  on  the  neutral  sphingomyelinase  and 
neutral ceramidase activities was investigated. 
Results 
IL-1/3 stimulates chronic activation of  neutral sphingomyelinase 
Previously,  it has been  shown that IL-113  causes  a rapid  (within  minutes) and  transient 
activation  of neutral  sphingomyelinase  activity  in  rat  mesangial  cells,  which  leads  to 
increased  ceramide  formation  [Huwiler  et al.  1996,  Kaszkin  et al.  1998].  Now,  these 
studies have been extended and it has been found that prolonged treatment of mesangial 
cells with IL-113 resulted in a delayed second peak of neutral sphingomyelinase activation 
that was first detectable after 2 h of stimulation and  reached a maximum after 4 h (Fig. 
4A).  The acid  sphingomyelinase also showed  a time-dependent delayed activation after 
IL-1  13  treatment (Fig. 48). 
When  the  level  of ceramide  was  measured  by  tandem  mass  spectrometry  after  IL-
113 stimulation,  no  increase  was  observed  up  to  24  h  after  stimulation  (Fig.  5),  thus 
pointing toward additional compensatory mechanisms that regulate the ceramide content 
of the cell. In contrast, 1 h of stimulation with a bacterial sphingomyelinase led to an 8-10-
fold increase in ceramide levels (Fig. 5). 
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Time course ofn.,..l~-induced neutral (A) and acid (B) sphingomyelinase activities in rat mesangiai cells. 
Confluent rat mesangial cells were stimulated for the indicated time periods with  IL-l~ (2 nM). Thereafter, ce1l1ysates containing  100 
J,lg  of protein  were  taken  for  in  vitro  neutral  (A)  or  acid  (B)  sphingomyelinase  activity  assay  as  described  under  2.6.6.2.  The 
[14C]pbosphocholine generated was extracted and  counted in a tJ-counter. Results  are expressed as a percent of control values and are 
means ± S.D. (n = 34). *p < 0.05; ••  p < 0.01 (statistically significant difference compared with the unstimulated control). 
Figure 5 
Time course ofIL-IJ3-induced ceramide formation in rat mesangial 
cells. 
Cells were stimulated  for the  indicated time periods  with vehicle 
(control),  JL..1~  (2  nM),  or  bacterial  sphingomyelinase  (bact 
SMase;  0.1  mil1iunit/ml).  Thereafter,  lipids  were  extracted,  and 
ceramide  was  analysed  by  liquid  chromatography-tandem  mass 
spectrometry as  described under 2.6.7.  Results are means  of two 
independent experiments performed in duplicate (n=4). 
IL-1fJ stimulates chronic activation of  a neutral ceramidase 
To investigate the effect of IL-1~ on the ceramide-degrading enzymes, rat mesangial cells 
were stimulated for different time periods with the cytokine,  and  ceramidase activity was 
measured. As  shown in  Fig.  6 (A and  B),  IL-1~ caused  a chronic activation of acid  and 
neutral ceramidases, with  maximal stimulation occurring 4 h after cytokine exposure and 
subsequently  declining  for  the  neutral  enzyme  (Fig.  6A).  This  decline  is  due  to  the 
induction of the inducible nitric oxide synthase (iNOS) by  IL-1~ fOllowed by the production 
of high concentrations of nitric oxide which in turn trigger proteolytic degradation of neutral 
ceramidase and loss of neutral ceramidase activity (chapter 3.2)  [Franzen et al.  2002a]. 
This notion is supported by co-stimulation of mesangial cells with the nitric oxide synthase 
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(NOS)-inhibitor  NG-monomethyl-L-arginine  (L-NMMA)  which  prevents  the  decline  of 
neutral ceramidase activity (Fig. 6C). 
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Time course ofIL-lp-induced neutral (A) and acid (8) ceramidase activities in rat mesangiai cells. 
Quiescent rat mesangial cells were stimulated for the indicated time periods with LIP (2 nM). Thereafter, celllysates containing  100 
Ilg of protein were taken  for  in  vitro neutral (A) or acid  (B) ceramidase activity assay as described  under 2.6.6.1.  [14C]sphingosine 
generated was separated by thin layer chromatography and evaluated on a Fuji phosphoimager.  Results  are expressed  as a percent of 
control values and  are means ± S.D. (n = 3-4). Neutral ceramidase activity in control cells was 23  ± 3.4 pmolfrnglh. Acid ceramidase 
activity in control cells was 450 ± 32.4 pmoVmglh.  *p < 0.05; *.p < 0.01;  ***p < 0.001  (statistically significant difference compared 
with the unstimulated control). 
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Time course of neutral ceramidase  activity in rat  mesangiaI  cells 
after co-stimulation with IL-Ijl and L-NMMA. 
Quiescent  rat  mesangial  cells  were  stimulated  for  the  indicated 
time  periods  wi1h  IL-l  ~  (2  nM)  plus  lrNMMA  (2  mM). 
Thereafter, cell lysates containing 100 ).lg of  protein were taken for 
in  vitro  neutral  ceramidase  activity  assay  as  described  under 
2.6.6.1.  [14C]sphingosine  generated  was  separated  by  thin  layer 
chromatography and  evaluated on a Fuji phosphoimager.  Resu1ts 
are expressed as a percent of control values and are means ± S.D. 
(n =  3-4). 
IL-1fJ-stimulation leads to neutral ceramidase mRNA and protein up-regulation 
To test whether the increase in neutral ceramidase activity is due to an increased amount 
of neutral  ceramidase  protein,  Western  blot analysis was  performed  using  a polyclonal 
antiserum  raised  against  a  peptide  comprising  the  N-terminus  of the  murine  neutral 
ceramidase.  The  antiserum  recognised  a double band  of -110-120 kOa.  This size is  in 
agreement with the recently described size of rat kidney neutral ceramidase [Mitsutake et 
al.  20011.  To  determine  whether  the  recognised  protein  does  indeed  show  neutral 
ceramidase activity, ceillysates from IL-1f3-stimulated mesangial cells were separated on 
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a MonoO column, and fractions were analysed by Western blotting (Fig.  7,  upper panel) 
and  for  neutral  ceramidase  activity (lower panel).  Earlier fractions  (fractions  9 and  10) 
showed  an  -94-kDa protein of still  unknown identity that was  recognised  by the neutral 
ceramidase antibody. Fractions 11  and 12 showed exclusive expression of a 110-120-kDa 
protein, the predicted size of rat neutral ceramidase [Mitsutake et al.  20011.  The neutral 
ceramidase activity was  highest in  fractions  11  and  12,  which  also showed  the highest 
protein  amounts,  thus  suggesting  that  this  band  is  indeed  a  neutral  ceramidase. 
Furthermore, we investigated whether the antibody could immunoprecipitate a fully active 
enzyme.  As  shown  in  Fig.  8,  Western  blot  analysis  of  the  supernatant  after 
immunoprecipitation of neutral ceramidase revealed  a disappearance of the protein that 
was dependent on the antibody dilution used (Fig. 8,  upper panel). Preimmune serum did 
not deplete the protein from the supernatant. In parallel, a reduction of neutral ceramidase 
activity was observed in the supernatant (Fig. 8, lower panel). Consistent with a depletion 
of the enzyme in  the supernatant, an  increased amount of enzyme was observed in the 
immunoprecipitates  by  Western  blotting  (Fig.  9).  However,  no  increased  neutral 
ceramidase  activity  was  recovered  in  the  immunoprecipitates  (data  not shown).  These 
data  suggest that binding  of the  antibody  to  its  antigen  leads  to  neutralisation  of the 
enzyme activity. 
Stimulation  of  mesangial  cells  with  IL-1~  led  to  a  marked  and  time-dependent  up-
regulation of the neutral ceramidase protein (Fig.  10A). In  contrast, the acid ceramidase 
protein, which runs at 55 kDa  as a holoenzyme under non reducing conditions [Bernardo 
et al.  19951, was not significantly changed (Fig. 10B). 
It  was  further  investigated  whether  the  up-regulation  of neutral  ceramidase  is  due  to 
increased de novo synthesis. For this purpose, mesangial cells were stimulated with  IL-1~ 
, for  different  time  periods,  and e 5 S1methionine  and  [35S1cysteine  were  included  in  the 
culture medium for the last 4 h of stimulation.  Thereafter,  the cells were lysed,  and  the 
neutral  ceramidase was immunoprecipitated and  analysed  by SDS-PAGE.  Fig.  5 shows 
that  IL-1~ triggered  increased  de  novo synthesis  of the  neutral  ceramidase.  A  similar 
increase was also observed with  another pro-inflammatory cytokine, TNF-o; (Fig.  11).  In 
contrast, the degradation of the neutral ceramidase was not affected by  IL-1~ treatment 
(data not shown) as  analysed  by pulse-chase experiments. In  a next step,  it was tested 
whether there is also an induction of the mRNA coding for the neutral ceramidase. Based 
on the mouse sequence of neutral ceramidase, mouse primers were selected and used to 
obtain  a  cDNA  for  the  rat  sequence.  Using  this  partial  sequence  of the  rat  neutral 
ceramidase, new primers were generated and used to perform reverse transcriptase-PCR 
of IL-1~-stimulated rat mesangial cells.  IL-1~ stimUlation indeed led to a clear induction of 
the neutral ceramidase mRNA level (Fig.  12). A maximal induction was obtained after 4 h 
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of stimulation and slightly decreased over the next 20 h. A similar induction was obtained 
in  mouse  mesangial  cells  using  mouse  primers  (data  not  shown).  Furthermore,  the 
induction of neutral  ceramidase  by  IL-1~ was  confirmed  by  Northern blot analysis (Fig. 
13).  Interestingly,  two  transcripts  were  detected  for  the  neutral  ceramidase  at  3.5 
kilobases,  which were both  induced by  IL-1~ (Fig.  13,  upper panel).  In contrast, the acid 
ceramidase mRNA was not significantly altered by  IL-1~ stimulation (Fig. 13, lower panel). 
Figure 7 
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Lysates  were  subjected to  irrunuDoprecipitation  using  either  the 
anti-neutral ceramidase antibody at the indicated dilutions or the 
preimmune serum at 1  :50.  Thereafter, aliquots of  the supernatant 
were  taken  for  Western  blot  analysis  using  the  anti-neutral 
ceramidase antibody at a dilution of 1  :500 (upper panel), or neutral 
ceramidase activity was measured (lower panel). 
Immunoprecipitates  were subjected to SDS-PAGE,  and Western 
blot  analysis  was  perfonned  using  the  anti-neutral  ceramidase 
antibody at a dilution of  1  :500. 
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IL-Ip treatment enhances neutral ceramidase protein levels in mesangial cells. 
Quiescent mesangial cells were stimulated for the indicated time periods with 2 nM IL-IJ3. Thereafter, ce1l1ysates were prepared, and 
100  J.1g  of protein were subjected to  SDS~PAGE  (7 and 10% acrylamide gels for the neutral and acid cerarnidases, respectively) and 
transferred to nitrocellulose membrane. Western blot analysis was perfonned using an anti-neutral ceramidase antiserum at a dilution of 
1:500 (A)  or an anti-acid ceramidase antiserum at a dilution of 1:2000 (B). Bands were visualised by the EeL methods. The blot is 
representative of  three independent experiments showing similar results. 
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nAp  stimulates  de  novo  synthesis  of neutral  ceramidase  in 
mesangiaI cells. 
Confluent  rat  mesangial  cells  were  stimulated  for  the  indicated 
time periods with  vehicle (control),  lL-lfl (2  nM),  or lNF-a (2 
nM).  During  the  last  4  h  of  stimulation,  a  mixture  of 
[3SS]methionine  and  eSS]cysteine  was  added.  Thereafter,  cell 
iysates  were  prepared,  and  the  neutral  ceramidase  was 
immunoprecipitated as described under 2.5.4. Immunoprecipitates 
were  separated  by  SDS-PAGE,  and  the  radioactive  amount  of 
neutral ceramidase was  evaluated on a Fuji phosphoimager. The 
data are expressed as a percent of control stimulation and are the 
means  of two  independent  experiments  perfonned  in duplicate 
(n=4).  *p  < 0.05j  *.p <  0.01  (statistically significant difference 
compared with the unstimulated control). 
It  was  further  investigated  whether  the  up-regulation  of neutral  ceramidase  is  due  to 
increased de novo synthesis_ For this purpose, mesangial cells were stimulated with  IL-1~ 
for  different  time  periods,  and  [3SSjmethionine  and  eSSjcysteine  were  included  in  the 
culture medium for the last 4 h of stimulation_  Thereafter, the cells were  lysed, and  the 
neutral  ceramidase was  immunoprecipitated and  analysed  by SOS-PAGE.  Fig_  5 shows 
that  IL-1~ triggered  increased  de  novo synthesis  of the  neutral  ceramidase_  A  similar 
increase was also observed with  another pro-inflammatory cytokine,  TNF-a (Fig_  11)_  In 
contrast, the  degradation of the neutral ceramidase was  not affected by  IL-1~ treatment 
(data not shown)  as  analysed by pulse-chase experiments_  In a next step,  it was tested 
whether there is also an induction of the mRNA coding for the neutral ceramidase_ Based 
on the mouse sequence of neutral ceramidase, mouse primers were selected and used to 
obtain  a  cONA  for  the  rat  sequence_  Using  this  partial  sequence  of the  rat  neutral 
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ceramidase, new primers were generated and used to perform reverse transcriptase-PCR 
of IL-1~-stimulated rat mesangial cells.  IL-1~ stimulation indeed led to a clear induction of 
the neutral ceramidase mRNA level (Fig.  12). A maximal induction was obtained after 4 h 
of stimulation and slightly decreased over the next 20 h. A similar induction was obtained 
in  mouse  mesangial  cells  using  mouse  primers  (data  not  shown).  Furthermore,  the 
induction of neutral  ceramidase by  IL-1~ was  confirmed  by Northern  blot analysis  (Fig. 
13).  Interestingly,  two  transcripts  were  detected  for  the  neutral  ceramidase  at  3.5 
kilo bases, which were both induced by  IL-1~ (Fig.  13, upper panel). In  contrast, the  acid 
ceramidase mRNA was not significantly altered by  IL-1~ stimulation (Fig. 13, lower panel). 
Figure 12 
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Quiescent  rat  mesangial  cells  were  stimulated  for  the  indicated 
time periods with JL.l (2 nM). Thereafter, RNA was prepared, and 
reverse transcriptase-PCR of the neutral ceramidase (upper panel) 
and  GAPDH  (lower  panel)  was  performed  as  described  under 
2.4.6. The data afe representative of  three independent experiments 
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Quiescent mesangial cells were stimulated for 4 and 8 h with IL-I 
(2  nM). Thereafter,  RNA  was  prepared,  separated  on  an  agarose 
gel,  and  transferred  to  a  nylon  membrane;  and  Northern  blot 
analysis was perfonned as described under 2.4.9 using a probe for 
the  rat  neutral  cerarnidase  (upper panel),  the  rat  acid ceramidase 
(lower  panel),  or  GAPDH  (middle  panel).  The  data  show  two 
independent stimulation experiments. 
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IL-1fJ-induced up-regulation of neutral ceramidase involves the p38-MAPK pathway, but 
not MAPKAPK-2 
To  further  elucidate  mechanistically  the  pathway  by  which  IL-1~  increases  neutral 
ceramidase activity, inhibitors against the different MAPK cascades were tested, i.e.  the 
classical ERK and the stress-activated protein kinase p38 MAPK, since these MAPKs are 
known to play an important role in activating transcription factors and subsequently gene 
transcription and are targeted by rather specific low molecular mass inhibitors. 
S8 202190, which is a quite selective inhibitor of p38 MAPK [Cuenda et al.  1995], caused 
a dose-dependent decrease in  IL-1~-induced neutral ceramidase activity (Fig.  14) as well 
as in protein induction (Fig.  15). S8 202190 alone had no effect on ceramidase activity or 
protein levels (Fig. 14 and  15). Consequently, it was found that co-treatment of IL-1~ with 
S8  202190,  which  blocks  neutral  ceramidase  activity,  but  leaves  the  IL-1~-induced 
persistent  sphingomyelinase  activation  unaffected,  resulted  in  increased  formation  of 
ceramide  (Fig.  16).  In  parallel,  an  enhanced  rate  of apoptosis  was  seen  under  co-
treatment  conditions  (data  not  shown).  S8  202190  had  no  effect  on  IL-1~-stimulated 
neutral  or  acid  sphingomyelinase  or  acid  ceramidase  activities  (data  not  shown).  In 
contrast to  S8 202190,  U0126,  which  inhibits the  MAPK  kinase  MEK,  and  Ro  318220, 
which  potently blocks protein  kinase  C isoenzymes,  were  ineffective in  blocking  neutral 
ceramidase activity (data not shown). 
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Effect oftbe p38 MAPK iohibitor SB  202190 on  IL-l~-induced 
neutral ceramidase acti vity 
Quiescent mesangial  cens  were  stimulated  for  8 h  with  vehicle 
(control), IL-lj3 (2 nM) in the presence of  the indicated micromolar 
concentrations  of SB  202190,  or  SB  202190  alone.  Thereafter, 
neutral  ceramidase  activity  was  detected  as  described  under 
2.6.1.1. Neutral ceramidase activity in control cells was 18.6 ± 2.8 
pmol/mg/h.  Results  are expressed as  a percent of control  values 
and are means ± S.D. (. =  3-4). 'p < 0.05; (statistically significant 
difference compared with the IL-lj}-stimulated control). 
Quiescent mesangiai  cells  were  stimulated  for  8  h with  vehicle 
(contro}), IL-lP (2 nM) in the presence of the indicated micromolar 
concentrations  of SB  202190, or SB  202190  alone.  Thereafter, 
protein levels were detected as described under 2.5.6. 
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["Cjserine-Iabelled cells were stimulated for 24 h with  IL-I~ (2 
nM) in the presence of  the indicated micromolar concentrations of 
SB 202190 or SB 202190 alone. Thereafter, lipids were extracted, 
and [14C]ceramide was analysed as described under 2.6.2. Results 
are expressed as a percent of control values and are means ± S.D. 
(n = 3-4). *p < 0.05; **p < 0.01  (statistically significant difference 
compared with the IL-I~-stimulated control). 
As  MAPKAPK-2  is  a  downstream  substrate  of p38  MAPK,  which  can  phosphorylate 
various transcription factors and  thereby regulate gene transcription [Rouse et al.  1994, 
Tan et al.  1996, Kotlyarov et al.  1999], it was further investigated whether MAPKAPK-2 is 
involved  in  IL-1p-mediated  neutral  ceramidase  activation.  For this  purpose,  mesangial 
cells from  MAPKAPK-2 knockout mice [Kotlyarov et al.  1999] and  corresponding control 
mice were isolated and  stimulated with IL-1p. As shown in Fig. 17,  IL-1p-induced neutral 
ceramidase activity was  not abolished  in  these mice,  thus suggesting that MAPKAPK-2 
does not mediate p38 MAPK-triggered neutral ceramidase induction. 
Figure 17 
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IL-Ip-stimulated  neutral  ceramidase  activity  in  mesangial  ceUs 
from MAPKAPK-2-deficient mice. 
Quiescent  mouse  mesangial  cells  from  control  C57IBL6  mice 
(BL6)  or  MAPKAPK-2  -1- mice  (MAPKAP-2K  -1-)  were 
stimulated  for  8  h  with  IL-I~  (2  nM).  Thereafter,  neutral 
ceramidase  activity  was  measured  as  described  under  2.6.1.1. 
Results are expressed as a percent of  control values and are means 
±  S.D.  (0 = 6).  Neutral cerarnidase activity in  control C57IBL6 
cells  was  38.4  ±  2.3  pmol!mg!h,  and  the  activity  in  control 
MAPKAPK-21 cells was 20.1  ± 4.5  pmol/mg/h. 'p < 0.05; "p < 
0.01  (statistically  significant  difference  compared  with  the 
corresponding unstimulated controls). 
In  this  part of the thesis,  it has  been  shown  that IL-1P  evokes  a biphasic activation  of 
neutral sphingomyelinase activity in renal mesangial cells. As previously reported,  a first 
peak of activation occurs after minutes of IL-1P stimulation, leading to increased ceramide 
levels in  mesangial cells  [Huwiler et al.  1996,  Kaszkin  et al.  1998].  Now,  these  studies 
have  been  extended  and  it  was  reported  on  a  second  increase  in  neutral 
sphingomyelinase activity occurring after hours of IL-1P  treatment.  Surprisingly, this late 
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phase of neutral sphingomyelinase activation is not paralleled by an increase in ceramide 
levels in the cells, thus arguing for additional counter-regulatory mechanisms that maintain 
a normal ceramide level.  Obvious candidates are ceramide-degrading  enzymes such as 
the ceramidases, which deacylate ceramide to form sphingosine.  Indeed,  activity assays 
for neutral and  acid ceramidases revealed that these enzymes are activated in a delayed 
fashion by Il-1  ~ after hours of stimulation. This increase in activity is due to transcriptional 
and translational activation of the gene, as both the mRNA level (Fig.  12 and  13) and the 
de  novo protein  synthesis  (Fig.  11)  of the  neutral  ceramidase  were  up-regulated.  The 
consequence of this dual action on the ceramide-generating and -degrading enzymes is a 
stable  level of ceramide,  which  even tends to decrease over prolonged time periods of 
stimulation.  Similar results  regarding  a  balanced  regulation  of neutral  ceramidase  and 
neutral  sphingomyelinase  activities  and  ceramide  levels  in  mesangial  cells  were  also 
observed for TNF-a [Huwiler at a/.  1999b]. 
These findings  are  consistent with  the  data of Nikolova-Karakashian  at a/.  [1997],  who 
found that, in rat hepatocytes,  Il-1~ also chronically increases neutral ceramidase activity 
and  fails  to  accumulate  ceramide  in  the  cells.  Additionally,  these  authors  found  that 
vanadate, a tyrosine phosphatase inhibitor, dramatically enhances  Il-1~-induced neutral 
ceramidase  activity,  whereas  the  nonspecific tyrosine kinase  inhibitor genistein  partially 
inhibits  it.  Whether this  is  due to  phosphorylation  and  subsequent changes  in  enzyme 
activity or changes in the expression level of the enzyme were not addressed. 
Furthermore, Coroneos at a/.  [1995] reported that platelet-derived growth factor is a potent 
activator of ceramidase activity in  rat mesangial  cells,  whereas cytokines such as  Il-1~ 
and TNF-a are ineffective in activating ceramidase after 1 h of stimUlation. These data do 
not contrast with our results, as  1 h of Il-1  ~ stimulation was not sufficient to increase the 
neutral  ceramidase  activity,  and  at  least  2-4  h  of stimulation  were  required  to  see 
significant stimUlation of enzyme activity (Fig. BA). 
Again,  the short-term activation of neutral/alkaline ceramidase by platelet-derived growth 
factor observed by Coroneos at a/.  [1995] was suggested to involve tyrosine kinases since 
the platelet-derived growth factor-induced activation was completely inhibited by genistein. 
Taken  together,  these  different results  make  it tempting  to  speculate  that  the  neutral 
ceramidase  is  regulated  by  two  different  mechanisms:  (i)  a  rapid  post-translational 
regulation by phosphorylation/dephosphorylation reactions,  which  is further supported by 
the  presence of various putative protein kinase phosphorylation sites in  the sequence of 
the  neutral  ceramidase,  and  (ii)  a  long-term  regulation  by  gene  transcription,  as 
documented for the first time in this study. 
Furthermore, the data reveal that p38 MAPK is critically involved in the up-regulation of Il-
1~-induced neutral  ceramidase  activity.  As  previously  reported,  Il-1~  indeed  potently 
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activates the p38  MAPK pathway in  mesangial cells [Guan  et a/.  1997]. p38  MAPK has 
been attributed an important role in transcription of many genes [Obata et al. 2000, Ono & 
Han  2000]  due  to  its ability to phosphorylate  and  activate various transcription  factors, 
including  activating  transcription  factor-2,  myocyte  enhancer  factor-2C,  and 
CHOP/GADD153,  which  is  a member of the  CAAT/enhancer-binding  protein  family  of 
transcription factors. Furthermore, p38 MAPK can phosphorylate and activate MAPKAPK-
2,  which  in  turn  can  phosphorylate  transcription  factors,  including  cAMP  response 
element-binding protein and activating transcription factor 1 [Tan et al.  1996], and thereby 
activate gene transcription. 
Using  mesangial  cells  from  MAPKAPK-2  knockout  mice  [Kotlyarov  et  al.  1999],  the 
involvement of MAPKAPK-2 in the cytokine-induced up-regulation of neutral ceramidase 
can,  however,  be  excluded.  The  exact  pathway  by  which  p38  MAPK  up-regulates the 
neutral ceramidase protein and activity is presently under investigation. 
This data further suggest an inverse correlation between neutral ceramidase activity and 
the rate of apoptosis. Whenever increased neutral ceramidase activity is observed, such 
as  after  IL-1~ treatment,  no  DNA fragmentation can  be detected [Huwiler et al.  1999b]. 
However,  when  neutral  ceramidase  activity  is  blocked  by  co-incubation  with  the  p38 
MAPK inhibitor SB 202190,  ceramide levels (Fig.  16) and  also DNA fragmentation (data 
not  shown)  are  increased.  Moreover,  when  neutral  ceramidase  activity drops,  such  as 
after nitric oxide  donor treatment,  an  increased  rate  of DNA fragmentation  is  observed 
[Huwiler  et al.  1999b].  However,  a causative  role  of increased  ceramide  levels  in  cell 
death  induction  is  controversial  and  not  yet  settled.  Some  studies  have  shown  that 
ceramide  activates  different  caspases  and  thereby  feeds  the  signal  into  the  apoptotic 
pathway  [Mizushima  et al.  1996,  Kuo  et al.  1997,  Tepper et al.  1997,  Machleidt et al. 
1998].  Other  reports  have  documented  that  ceramide  can  inhibit  the  survival  signal 
resulting  from  the  phosphatidylinositol  3-kinase  cascade  [Zhou  et  al.  1998,  Zundel  & 
Giaccia 1998], and  it may well be that turning off a survival signal will finally direct a cell 
toward apoptosis. 
Further evidence  for  an  involvement of ceramidases  in  cell  survival  has  recently  been 
forwarded by Strelow et al.  [2000]. These authors showed that overexpression of the acid 
ceramidase  in  fibroblast  L292  cells  leads  to  reduced  TNF-a-induced  apoptosis.  In 
contrast, Tohyama et al. [1999] and Segui et al. [2000] reported that fibroblasts [T ohyama 
et al.  1999] and  lymphoid cells [Segui  et al.  2000] from  patients suffering from  Farber's 
disease, which results in a deficiency in acid ceramidase activity, do not show enhanced 
rates of apoptosis compared with healthy controls. 
Another  interesting  observation  of this  study  is  the  appearance  of a  double  band  in 
Northern  blot  analysis  (Fig.  13)  as  well  as  Western  blot  analysis  (Fig.  10A).  It is  very 
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tempting to speculate that these two bands represent different splice variants or isoforms 
of the neutral ceramidase.  However,  additional work is  needed to unambiguously define 
the identity of both bands.  In  any case, the pathways controlling ceramide levels in  cells 
exposed  to  stressful  stimUli  such  as  inflammatory cytokines  seem  to  exert a stringent 
control on  both the ceramide-generating  enzymes as well as  the ceramide-metabolising 
enzymes, thus arguing for the relevance of ceramide and the products derived thereof for 
cellular functions. 
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3.2  Nitric  oxide  induces  degradation  of the  neutral  ceramidase  in  rat  renal 
mesangial cells and is counterregulated by protein kinase C. 
Introduction 
In  recent  years,  nitric  oxide  (NO),  has  become  established  as  a  diffusible  universal 
messenger  mediating  cell-cell  communication  throughout  the  body.  Excessive  and 
uncontrolled  production  of NO  is  associated  with  severe  diseases  like  septic  shock, 
stroke,  neurodegeneration,  diabetes  mellitus,  arthritis,  and  other  forms  of acute  and 
chronic  inflammation  [Nathan  1992,  Knowles  &  Moncada  1994,  Kroncke  et  al.  1995, 
Pfeilschifter 1995].  NO-induced apoptosis has been described for a variety of cell types 
but it seems to be a matter of concentration whether NO acts pro- or anti-apoptotic [Brune 
et al.  1998, Beck et al.  1999]. The early and  rapid  mechanisms of NO signalling depend 
primarily  on  post-translational  modifications  of  pre-existing  cellular  proteins  such  as 
guanylate  cyclase.  However,  the  late  phases  that  are  required  to  accommodate  the 
microenvironmental changes are mediated by alterations in gene expression [Pfeilschifter 
et al. 2001 a, Pfeilschifter et al. 2001 b]. 
Previously,  it  was  shown  that glomerular  cells  exposed  to  NO  donors  respond  with  a 
drastic increase in ceramide formation  [Huwiler et al.  1999a, Huwiler et al.  1999b]. This 
was due to a dual action of NO, on one side by activation of sphingomyelinases, and on 
the other side by inhibition of ceramidase activities. In this part, the mechanism by which 
NO reduces neutral ceramidase activity in mesangial cells was investigated. 
Results 
Nitric oxide  stimulation  leads  to  a  decrease  in  neutral ceramidase  activity and protein 
level. 
Recently,  it has been demonstrated that high  levels of nitric oxide caused  an  increased 
ceramide  formation  with  subsequent  apoptosis  of mesangial  cells  which  was  due  to 
enhanced  sphingomyelinase  activity  and  reduced  ceramidase  activity  [Huwiler  et  al. 
1999b].  These  studies  were  now  extended  and  the  mechanism  by  which  NO  inhibits 
ceramidase activity was investigated. Stimulation of renal  mesangial cells with the  nitric 
oxide donor spermine-NO  leads to a delayed  and  time-dependent reduction  of neutral 
ceramidase  activity (Fig.  18A) with  a first significant effect after 8 h of treatment. This 
reduction of activity is paralleled by a decrease of neutral ceramidase protein amount as 
shown  by  a Western blot analysis  (Fig.  18B). The effect on  neutral ceramidase activity 
(Fig.  19A),  and  protein  level  (Fig.  19B) occurs  in  a concentration-dependent manner. A 
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TIme-dependent effect of  spennine~NO  on neutral ceramidase activity (A) and protein (B) in rat mesangial cens. 
Confluent rat mesangial cells were stimulated for the indicated time periods with spennine-NO (SP-NO; O.5mM). Thereafter, celllysates 
containing  IOOJ,tg of  protein were taken for a neutral ceramidase activity assay (A) or SDS-PAGE (7% acrylamide gel) and subsequent 
Western blot analysis  (B) as  described in chapters 2.5.6.  and 2.6.1.1. The generated [14C]sphingosine  was separated on thin layer 
chromatography and evaluated on an Imaging System (Fuji).  Results in A are expressed as % of control values and  are means ±S.D. 
(n=3-4). Neutral ceramidase activity in control cells was 21.5 ± 2.5 pmollrnglh. **p<O.OI statistically significant difference compared to 
the unstimulated control. Data in B are representative of  at least 3 independent experiments giving similar results. 
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Concentration-dependent effect of spermine-NO on neutral ceramidase activity and protein level in rat mesangial cells. 
Quiescent rat mesangial cells were stimulated for 24h with the indicated concentrations of spermine-NO (SP-NO;  in mM) (A and B). 
Thereafter,  cell  lysates  containing  IOOJ..lg  of protein  were  taken  for  a neutral  ceramidase  activity  assay  (A)  or  SDS-PAGE  (7% 
aczylamide gel) and subsequent Western blot analysis (B) as described in chapters 2.5.6 and 2.6.1.1. The generated [14C]sphingosine was 
separated on thin layer chromatography and evaluated on an Imaging System (Fuji). Data in A are expressed as % of  control values and 
are means  ±S.D.  (n=3-4).  Neutral  ceramidase activity in  control  cens  was  20.8  ± 3.0 pmol/mg/h.  "'p<0.05,  "'*p<O.Ol,  statistically 
significant difference compared to the. unstimulated control.  Data in B are representative of 3 independent experiments giving similar 
results. 
maximal  reduction  to  approximately  60%  of control  level  is  obtained  with  0.3  mM  of 
spermine-NO  which  is  not further  reduced  by  increasing  the  concentration  of the  NO 
donor. Interestingly, the protein level of neutral ceramidase is almost completely reduced 
at 0.3  mM  of NO.  The total amount of protein was  not changed  upon  NO-treatment as 
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shown by staining for the housekeeping enzyme ~-actin (Fig. 18B and  19B, lower panels). 
To verify that the observed effect of spermine-NO is indeed mediated by released NO and 
not by an unspecific effect, spermine was used as a control substance. As seen in Fig. 20, 
spermine  has  no  effect  on  neutral  ceramidase  protein  levels  nor on  activity  (data  not 
shown).  Furthermore, Deta-NO, another NO donor which possesses a much longer half-
life than spermine-NO,  shows the  same  effect on  ceramidase  protein  degradation (Fig. 
20) 
Figure 20 
Quiescent  rat  mesangial  cells  were  stimulated  for  24h  with  the 
indicated  concentrations  of spennine (SP;  O.5mM).  spenmne-NO 
+--",,",'"  (SP·NO;  O.5mM)  or DETA·NO (O.5mM).  Thereafter,  cell  lysate, 
cenvnlda ••  containing  lOOj.lg  of protein  were  taken  for  SDS-PAGE  (7% 
acryiamide gel) and subsequent Western blot analysis as described 
under 2.5.6. 
Activation of  PKC prevents NO-induced down-regulation of  neutral ceramidase activity 
and protein. 
When  mesangial  cells  were  exposed  to  NO  donors in the  presence  of phorbol  esters 
which  directly activate  PKC,  both  ceramide  accumulation  and  DNA fragmentation were 
completely blocked [Huwiler et al.  1999b]. Therefore, the effect of PKC on the NO-induced 
down-regulation  of neutral  ceramidase  was  investigated.  Treatment of mesangial  cells 
with spermine-NO in the presence of 12-0-tetradecanoylphorbol-13-actetate (TPA) dose-
dependently reversed the inhibitory action of NO on neutral ceramidase activity (Fig. 21A). 
In parallel, the protein level of neutral ceramidase also recovered in the presence of TPA 
(Fig. 21B). Neither short-term nor long-term stimulation with TPA alone had any effect on 
neutral ceramidase activity or protein level (data not shown). 
Furthermore,  physiological  activators  of  PKC,  like  platelet-derived  growth  factor  BB 
(PDGF-BB),  angiotensin  II  and  the  stable  ATP  analog  y-S-ATP,  which  all  evoke 
phosphoinositide  hydrolysis  and  generation  of  1,2-diacylglycerol,  the  endogenous 
activator of PKC [Pfeilschifter 1986, Pfeilschifter 1990, Pfeilschifter & Hosang 1991], were 
tested.  All  these substances mimicked the effect of TPA and  reversed the NO-mediated 
inhibition of neutral ceramidase activity (Fig.  22A) , as well as neutral ceramidase protein 
level (Fig. 22B).  Consistent with the observed increase of neutral ceramidase protein by 
all  PKC  activators,  a decrease of NO-induced  ceramide  formation  was  found  by  these 
substances  in  intact  mesangial  cells  when  performing  mass spectrometry of extracted 
lipids (Fig. 23). 
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Effect, of  protein kinase C on NO~reduced neutral ceramidase activity (A) and neutral ceramidase protein (8) in rat mesangial cells. 
Confluent rat mesangial cells  were stimulated for 24 h  with vehicle (control)  or spermine-NO (SP-NO;  1.OmM)  in the absence or 
presence of the indicated concentrations of the phorbol ester TPA (in nM). Thereafter, cen lysates containing  lOOJ!g of protein were 
taken for  a neutral ceramidase activity assay (A) or SDS-PAGE (7% acryJamide gel) and subsequent Western blot analysis (B) as 
described in chapter 2.5.6 and 2.6.1.1. The generated [14C]sphingosine was separated on thin layer chromatography and evaluated on an 
hnaging System (Fuji). Results in A are expressed as % of control values and are means ±S.D. (n=34). Neutral ceramidase activity in 
control cells was 24.5  ± 2.1  pmoVmg!h. Data in B are representative of2 independent experiments giving similar results. 
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Effect ofTPA, PDGF, angiotensin n  and y-S-ATP on NO-reduced neutral cemrnidase activity (A) and protein level (B) 
Quiescent rat mesangial cells were stimulated for 24h with either vehicle (control) or spermine-NO (SP-NO; 1.0mM) in the absence or 
presence ofTPA  (l.O~M), PDGF-BB (3.0ng/ml), angiotensin n  (IOOnM) ory-S-ATP (lOO~M)  as indicated. 
(A) Cell Iysates containing 100llg of protein were taken for a neutral ceramidase activity assay as described in chapter 2.6.1.1. The 
generated  [14C]sphingosine  was  separated  on thin layer chromatography and evaluated on  an hnaging  S~tem (Fuji).  Results are 
expressed as % of  control values and are means tS.D. (n=4). *p<0.05, **p<O.Ol, statistica1ly significant difference compared to the NO-
stimulated control. Neutral ceramidase activity in control cells was 27.3 t  1.0 pmoVmg!h. 
(B)  Cen Iysates  containing  IOO~g of protein  were  sUbjected  to  SDS-PAGE (7% acrylarnide gel) and tmnsferred to  nitrocellulose 
membrane.  Western  blot  analysis  was  performed  using  an  anti-neutral  ceramidase  antiserum  at  a  dilution  of 1:500.  Data  are 
representative of2 independent experiments giving similar results. 
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Effect of TPA, PDGF, angiotensin II and y-S-ATP on NO-induced 
ceramide formation. 
Quiescent  rat  mesangial  cells were stimulated  for  24h  with  either 
vehicle (control) or spennine-NO (SP-NO;  I.OmM) in the absence 
or presence of TPA (I.O"M), PDGF-BB (3.0ni¥ml), angiotensin II 
(IOOnM)  or y-S-ATP (lOO"M) as indicated. lipids were extracted 
and  ceramide  was  analysed  by  LCIMSIMS  spectrometry  as 
described  under 2.6.2.  Results are  means ± S.D.  (n:q). *p<O.05 
statistically significant  difference  compared  to  the  NO-stimulated 
control. 
The effect of angiotensin" was further characterised and  was found to involve the AT1 -
receptor. The protective effect of angiotensin  "  reversing the  NO-mediated  inhibition of 
neutral ceramidase  activity (Fig.  22A) , as well  as  neutral  ceramidase protein  level  (Fig. 
22B) was  abrogated by co-stimulation with  valsartan (Fig. 24),  a specific inhibitor of the 
AT1 -receptor-subtype [Criscione  et al.  1993,  Timmermans  et al.  1993].  In  contrast,  the 
specific  AT2-receptor-agonist  CGP  42112A  [Hines  et  al.  2001]  delivers  no  further 
activation  compared  to  the  reversion  of neutral  ceramidase  activity  and  protein  by 
angiotensin  "  alone  (Fig.  24).  To  definitely  exclude  that  the  protective  effect  is  not 
mediated by the AT2-receptor a specific AT2-receptor antagonist like PO 123319 [Blankley 
et al.  1991] has to be evaluated. In this context, it is important to note that mesangial cells 
exclusively express the AT1 receptor [Pfeilschifter 1989, Pfeilschifter et al.  1990]. 
NO promotes degradation of  neutral ceramidase. 
To investigate  how  NO  down-regulates  the  protein  amount of neutral  ceramidase,  the 
protein synthesis inhibitor cycloheximide [Ch'ih et al.  1979] was used. As seen in Fig. 25, 
the  presence of cycloheximide does not abrogate the NO-mediated reduction  of neutral 
ceramide protein nor does it affect the reversal by the PKC activators TPA, angiotensin" 
or y-S-ATP,  thus  suggesting that NO  modulates the degradation of neutral  ceramidase 
rather than its de-novo synthesis. 
Furthermore,  the  involvement  of  caspases  in  mediating  NO-induced  degradation  of 
neutral ceramidase was investigated. For this purpose, the broad caspase family inhibitor 
Z-VAO-FMK  as  well  as  the  specific  caspase-3  inhibitor  Z-OEVO-FMK  were  tested. 
However, none of these two inhibitors is able to block NO-induced enzyme degradation at 
the recommended concentration of  211M  (data not shown). In contrast, the highly selective 
proteasome  inhibitor  lactacystin  inhibited  the  NO-induced  degradation  of  neutral 
ceramidase (Fig. 26). Figure 24 
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Effect of  angiotensin IT. CGP 42112A and valsartan on NO-reduced neutral ceramidase activity (A) and protein level (B) 
Quiescent rat mesangial cells were stimulated for 24h with either vehicle (control) or spennine-NO (SP-NO; 1.0mM) in the absence or 
presence of  angiotensin IT (All, IOOnM). CGP 42112A (1 O~M). or valsartan (1 O~M)  as indicated. 
(A) Cell lysates containing lOOllg of  protein were taken for a neutral ceramidase activity assay as described in chapter 2.6.1.1. The 
generated  [14C]sphingosine  was  separated on thin layer chromatography and evaluated  on an Imaging System (Fuji),  Results are 
expressed as % of  control values and are means ±S.D. (n=4). Neutral ceramidase activity in control cens was 27.3 ± 1.0 pmol/mglh. 
(B)  Cell  Iysates  containing  IOO~g of protein  were subjected to  SDS-PAGE  (7%  actylamide gel)  and transferred to nitrocellulose 
membrane.  Western  blot  analysis  was  perfonned  using  an  anti-neutral  ceramidase  antiserum  at  a  dilution  of 1  :500.  Data  are 
representative of  2 independent experiments giving similar results. 
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Effect of  cycloheximide on NO-reduced neutral ceramidase protein level in mesangial cells. 
+- neutral 
ceramidase 
Quiescent mesangial cells were stimulated for 24h in the absence or presence of  cycloheximide (CHXj IOIlM) with either vehicle (-) or 
spennino-NO (SP-NO;  l.OmM) in the absence or presence of TPA  (l.O~M). angiotensin  IT  (All,  IOOnM)  or y-S-ATP  (lOO~M). 
Thereafter, cell lysates containing 100llg of  protein were subjected to SDS-PAGE (7% acrylamide gel) and transferred to nitrocellulose 
membrane.  Western  blot  analysis  was  perfonned  using  an  anti-neutral  ceramidase  antiserum  at  a  dilution  of 1:500.  Data  are 
representative of2 independent experiments giving similar results. 
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Effect ofJactacystin on NO-reduced neutral ceramidase protein level in mesangial cells. 
Results 
CelIs  were  stimulated  for  24h  in  the  absence  or presence of lactacystin  (20J,lM;  pretreated  for 2 h)  with  either  vehicle  (control)  or 
'pennino-NO (SP-NO;  1.0mM). Thereafter. cell lysate, containing IOOl'g of  protein were subjected to SDS-PAGE (7% acryIamide gel) 
and  transferred  to  nitrocellulose  membrane.  Western  blot  analysis  was  perfonned  using  an  anti-neutral  ceramidase  antiserum  at  a 
dilution of  1  :500. Data are "representative of 3 independent experiments giving similar results. 
PKC activation induces phosphorylation of  neutral ceramidase. 
To study whether PKC exerts its effect on neutral ceramidase via  phosphorylation of the 
enzyme  either  directly  or  indirectly  we  performed  in  vivo  phosphorylation  assays. 
Mesangial  cells  were  labelled  with  32p-orthophosphate  before  stimUlation.  Thereafter. 
neutral ceramidase was immunoprecipitated and incorporated 32p was analysed. As seen 
in  Fig.  27. stimulation of cells for 10 min with TPA causes a dose-dependent increase of 
phosphorylated neutral ceramidase. Similarly. PDGF-BB (Fig. 27) and angiotensin II (Fig. 
28)  also  induce  phosphorylation  of the  enzyme.  The  TPA-induced  phosphorylation  is 
inhibited  by the potent PKC  inhibitor Ro 318220 [Wilkinson et al.  1993] but not by CGP 
41251  [Meyer  et al.  1989].  an  inhibitor that  preferentially  blocks  Ca2 +-dependent  PKC 
isoenzymes (Fig. 29) [Ochsner et al.  1993. Marte et al.  1994]. 
Moreover.  it  was  investigated  whether  PKC  directly  phosphorylates  the  neutral 
ceramidase  in  an  in-vitro  system.  Neutral  ceramidase  was  enriched  by 
immunoprecipitating the enzyme from  unstimulated mesangial cell Iysates. and was then 
incubated  with  recombinant  PKC  of  the  four  subtypes  that  have  been  identified  in 
mesangial cells. i.e. PKC-a. -0. -E and ~  [Huwiler et al.  1991. 1992. 1993]. 
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minutes 
32P-IabeUed mesangial celis were stimulated for  15 min with either vehicle (control) or the indicated concentrations ofTPA(Figure27; 
in nM) and PDGF-BB (Figure 27; in nglmI). or for the indicated time perind, with angiotensin II (A II) (Figure 28; 100nM). Cells were 
then  lysed  and  neutral  ceramidase  was  immunoprecipitated  with  a polycional  antibody  at  a dilution of 1:100,  as  described  in  the 
materials  and  methods  section.  The  immunoprecipitates  were  separated  by  SDS-PAGE  (7%  aCIYlamide gels)  and  visualised  on  an 
Imaging System (Fuji). Data are representative of  3 independent experiments giving similar results. Figure 29 
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Effect  of PKC  inhibitors  on  TPA-induced  phosphorylation  of 
neutral ceramidase in mesangiai cells. 
32P_IabeIIed  mesangial  cells  were  preincubated  for  20 min  with 
either  Ro  318220  (1.0~M)  or  CGP  41251  (1.0~M)  before 
stimulation with TPA (100nM) for  10 min. Cells were then lysed 
and neutral ceramidase was imrnunoprecipitated with a polyclonal 
antibody at a dilution of 1: 1  00, as described  in the materials and 
methods section. The immunoprecipitates were separated by SDS-
PAGE (7% acrylamide gels) and visualised on an hnaging System 
(Fuji), Data are representative ef2 independent experiments giving 
similar results. 
Effect  of recombinant  PKC  isoenzymes  on  neutral  ceramidase 
phosphorylation in vitro. 
lllg of recombinant  PKC-a. -8. -E,  and -{ isoenzymes or buffer 
(control) were incubated  for  15 min with neutral  cerarnidase that 
was inununoprecipitated from unstimulated mesangial cells (upper 
panel) or with myelin basic protein (lower panel), as described in 
the  materia1s  and  methods  section.  Thereafter,  samples  were 
separated  on  SDS-PAGE  (7%  acry1amide  gel  for  neutral 
ceramidase  and  13%  for  MBP)  and  analysed  on  an  hnaging 
System  (Fuji).  Data  are  representative  of  2  independent 
experiments giving similar results. 
As  seen  in  Fig.  30,  upper panel,  PKC-I)  is  the  most efficient isoform  to  phosphorylate 
neutral ceramidase,  which appears as  a double band  at  approximately 120 kOa.  PKC-a 
and  PKC-~ induce  only  minor phosphorylation  of the  neutral  ceramidase.  In  contrast, 
PKC-e has no effect. 
To  verify that all  PKC  isoenzymes used  are active  enzymes,  phosphorylation of myelin 
basic protein (MBP),  which  is a well accepted substrate for PKC isoenzymes [Geiges et 
at.  1997]  is  shown  (Fig.  30,  lower  panel).  It  was  further  investigated  whether  the 
phosphorylation of neutral ceramidase by PKC in vitro occurs at the same phosphorylation 
sites  as  in  intact  cells.  For  this  the  phosphorylation  pattern  of in  vivo  phosphorylated 
neutral  ceramidase  was  compared  to  in  vitro  phosphorylated  ceramidase  after trypsin 
digestion. As seen in  Fig.  31A, C
2p]phosphorylated ceramidase from in  vivo and in vitro 
assays runs at 120 kOa on  a 7% Tris-glycine gel system. Upon trypsin digestion, enzyme 
preparations  are  both fragmented  into an  identical pattern of polypeptides.  Using  a 10-
20% gradient Tris-tricine gel system to allow a better separation of small polypeptides, two 
radioactive fragments between 15-20 kOa can be detected (Fig. 31B). 
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Results 
in vivo  in vitro 
Neutral ceramidase,  either purified from mesangial cells and subjected to in  vitro phosporylation by PKC-O  (A, right lane) or affinity-
purified from  in  vivo-Pj-label1ed TPA-stimulated mesangiaI cells (A, left lane), was digested with trypsin as described in the materials 
and methods  section.  Undigested control samples were  separated on a  Tris-glycine SDS-PAGE (7% acrylamide gel)  (A)  whereas 
trypsin-digested samples were separated on a Tris-tricine SDS-PAGE (10-20% gradient) (B). Gels were analysed on an Imaging system 
(Fuji) for radioactive fragments. 
Discussion 
Mesangial cells have been  shown to respond to high amounts of NO  with  an  increased 
generation of the sphingolipid molecule ceramide, which involves a dual mechanism, the 
activation  of sphingomyelinases and  the  concomitant  inhibition  of ceramidase  activities 
[Huwiler et al. 1999b]. 
In this part of the study, the mechanism by which NO reduces neutral ceramidase activity 
was  investigated.  The  data  clearly  show  that  the  NO-mediated  reduction  of neutral 
ceramidase  activity  is  paralleled  by  a  decrease  of the  ceramidase  protein  level.  This 
suggests that either the de-novo synthesis of neutral ceramidase is blocked by NO or that 
NO  induces degradation of the enzyme. The experiments performed in  the presence of 
the  protein  synthesis  inhibitor  cycloheximide,  which  does  not  affect  the  NO-triggered 
down-regulation nor the  basal level of neutral ceramidase (Fig. 25)  rather argues for an 
increased  degradation  of  the  enzyme.  This  notion  is  further  substantiated  by  the 
observation  that  a  specific  proteasome  inhibitor  blocked  NO-induced  ceramidase 
degradation, whereas several caspase inhibitors were without effect. Thus ceramidase is 
targeted by the ubiquitin proteasome machinery in mesangial cells.  Interestingly, the NO-
mediated degradation of ceramidase can be reversed by PKC  activating agents, like the 
phorbol ester TPA, but also the physiologically important ligands PDGF-BB, angiotensin II 
and  ATP.  The mechanisms by which  PKC  prevents degradation is  still  unclear but it is Results 
tempting  to  speculate  that  phosphorylation  events  on  neutral  ceramidase  play  an 
important role. 
Phosphorylation  is a well  known mechanism for regulating  protein stability.  Thus many 
proteins  are. subjected  to phosphorylation  and  as  a  consequence  are  degraded  more 
rapidly,  like the inhibitor of 1Cb  (Ix:B)  [Steffan  et al.  1995], the transcription factor ReIB, 
which is a member of the ReI/NF-x:B family of transcription factors [Marienfeld et al. 2001] 
or  the  tumor  suppressor  protein  p53  [Chernov  et  al.  2001].  On  the  contrary, 
phosphorylation  may  also  stabilise  certain  proteins  like  the  epidermal  growth  factor 
receptor [Bao et al.  2000], the growth arrest and  DNA-damage-inducible gene Gadd45 
[Leung et al. 2001], or the human proto-oncogene ets-2 [Fujiwara et al.  1988], and thereby 
lead  to  their  accumulation.  In  the  case  of  neutral  ceramidase,  it  seems  that 
phosphorylation of the enzyme by PKC directly or indirectly by alteration of another kinase 
or phosphatase activity, leads to reduced protein degradation. Our data further suggest, 
that in  mesangial cells,  the  PKC-3  isoenzyme is  the  most likely candidate  for a direct 
stabilising effect. This finding is corroborated by the fact that (i) only the broad spectrum 
PKC inhibitor Ro 31-8220, but not the inhibitor of the Ca 2+-dependent PKC isoenzymes, 
CGP 41251, is able to block TPA-stimulated phosphorylation of neutral ceramidase, and 
that  (ii)  recombinant  PKC-3  is  the  most  effective  isoform  to  phosphorylate  neutral 
ceramidase  in  an  in  vitro  system.  In  accordance  with  our  data,  Leung  et al.  [2001] 
reported  that PKC-3 plays an  important role  in  protein  stabilisation of Gadd45 in A431 
cells.  Mechanistically,  they showed  that epidermal  growth  factor,  by  activating  PKC-3, 
decreased  ubiquitination of Gadd45,  an  effect that was  blocked  by the PKC-3 selective 
inhibitor rottlerin.  It is tempting to speculate that PKC-3 also decreases ubiquitination of 
neutral ceramidase and thus stabilises the enzyme in mesangial cells. 
By sequence analysis of neutral ceramidase, nine putative PKC and several casein kinase 
II consensus phosphorylation sites can be found in the primary sequence [Mitsutake et al. 
2001].  However, site directed mutagenesis studies of these phosphorylation sites will  be 
required in order to identify which of these putative PKC phosphorylation sites, if any, are 
indeed relevant for ceramidase stability. 
Remarkably,  phosphorylation  of neutral  ceramidase  per se,  either by  PKC  or another 
kinase,  seems not to be sufficient for activation,  since short-term stimulation with either 
TPA, PDGF-BB or angiotensin II  did not change the enzyme's activity (data not shown). 
This contrasts to a report by Coroneos et al.  [1995], who found that PDGF activated an 
alkaline  ceramidase  in  mesangial  cells.  This  activation  was  under the  regulation  of a 
tyrosine phosphatase because activity increased in the presence of vanadate.  Whether 
this alkaline ceramidase is identical to the neutral ceramidase investigated in this study is 
not clear, since no biochemical characterisation of the alkaline enzyme has been reported. 
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Moreover,  when  we  added  vanadate  to  mesangial  cells,  it  had  no  effect  on  neutral 
ceramidase activity (data not shown). 
One obvious cellular consequence of neutral ceramidase stabilisation by PKC is  a more 
efficient elimination of ceramide which in turn may protect the cell  from the proapoptotic 
action  of this  lipid  mediator.  There  is  increasing  evidence  that  PKC  can  act  as  a 
cytoprotective  enzyme  preventing  stress-induced  programmed  cell  death  (apoptosis)  in 
various cell types, including mesangial cells [Huwiler et a/.  1999b, Meinhardt et a/.  2000]. 
Furthermore,  Jun  et a/.  [1999]  described  that  overexpression  of  PKC-~",  -15  and  -'11 
isoenzymes protected RAW 264.7 macrophages from NO-induced apoptosis by blocking 
NO-activating effects on  c-Jun N-terminal kinase/stress-activated protein kinase and p38 
kinase.  Moreover, overexpression of PKC-a in  320 myeloid progenitor cells leads to an 
increased  activation  of the  protein  kinase  B/Akt which  promotes  cell  survival  [Li  et a/. 
1999].  Obviously,  there  is  a  cell  type-specific  involvement  of PKC  isoenzymes  in  cell 
protection. In all, it is tempting to speculate that especially PKC-/i is a prime candidate for 
exerting an anti-apoptotic effect in mesangial cells via stabilising neutral ceramidase. This 
fits to previous  findings  and  hypothesis that  PKC-/i mediates  mitogen-activated  protein 
kinase activation in mesangial cells and promotes proliferation in response to extracellular 
nucleotides [Huwiler & Pfeilschifter 1994]. 
In  this  context  it  is  worth  noting  that  ceramide  is  able  to  directly  bind  to  PKC-/i  in 
mesangial  cells  [Huwiler  et  a/.  1998].  Such  a  binding  leads  to  a  decreased 
autophosphorylation  of PKC-/i  probably  ref/ecting  an  inhibitory effect on  the  enzyme's 
activity. This may constitute an intriguing positive feedback loop, with increased ceramide 
levels causing inhibition  of PKC-/i  , which  in  turn  leads to  an  increased degradation  of 
neutral  ceramidase  and  amplified  ceramide  accumulation.  Powerful  negatively  acting 
regulatory  pathways  are  required  to  terminate  amplification  loops  such  as  the  one 
suggested  here.  Noteworthy,  ceramide  also  binds  to  and  triggers  PKC-a-mediated 
feedback inhibition of cytokine-induced ceramide formation [Huwiler et a/.  1998,  Kaszkin 
et  al.  1998,  Pfeilschifter  & Huwiler  2000].  Can  these  seeming  disparate  results  be 
reconciled? It is suggesting that ceramide acts as a negative feedback regulator to control 
its own synthesis in response to cytokine stimulation via PKC-a activation, but as soon as 
a critical threshold of activation is  reached  and  high amounts of NO are  produced by a 
delayed  cytokine-induced  expression  of  the  inducible  NO-synthase,  ceramide  now 
functions  as  a  positive  feedback  modulator,  to  amplify  its  production  via  ceramidase 
destabilisation due to inhibition of PKC-/i.  This may operate in  a switch like mechanism 
[Pfeilschifter  et  a/.  2002]  and  initiate  programmed  cell  death  which  is  a  common 
phenomenon  in  acute  inflammation  as  well  as  resolution  of disease [Savill  & Johnson 
1995]. 
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Taken  together  the  results  of this  chapter  provide  evidence  that  NO  blocks  neutral 
ceramidase  activity by inducing  degradation  of the  enzyme  and  that this  effect can  be 
reversed  by activating PKC,  especially the ll--isoform. The neutral ceramidase may thus 
represent  a  novel  attractive  target  to  interfere  with  cellular  stresS  response  and  to 
modulate  programmed  cell  death  which  is  a  typical  feature  of  many  inflammatory 
diseases. Results 
3.3  Nitric  oxide  induces  neutral  ceramidase  degradation  by  the 
ubiquitin/proteasome complex in renal mesangial cells. 
Introduction 
The ubiquitin/proteasome system is the major pathway of selective protein degradation in 
eukaryotic cells.  Degradation  of a protein  via  this  system  occurs  via  three  distinct and 
successive steps.  Initially, the target proteins are conjugated to the polypeptide ubiquitin; 
in  the  second  step,  the  ubiquitin-conjugated  proteins  are  recognised  by  the  26S 
proteasome,  a large,  multicatalytic protease,  and  in  a last step degraded. The ubiquitin 
system targets normal short-lived proteins and  misfolded or otherwise abnormal proteins 
for degradation. Although the components of  the ubiquitin system are cytosolic, the known 
targets of the system  comprise not only soluble cytosolic and  nuclear proteins, but also 
membrane  proteins  and  even  luminal  endoplasmic  reticulum  (ER)  proteins.  Some 
misfolded ER proteins were shown to be retransported to the cytosol,  ubiquitinated, and 
then degraded by the proteasome [Plemper & Wolf 1999]. 
Results 
To test whether the degradation of neutral ceramidase induced by nitric oxide is mediated 
through  the  ubiquitin/proteasome  system,  lactacystin,  a  highly  selective  and  cell 
permeable inhibitor of the ubiquitine/proteasome complex, was applied. Analysing neutral 
ceramidase protein levels by immunodetection of mesangial.cell Iysates reveals that the 
NO  donor  spermine-NO  leads  to  a  concentration-dependent  down-regulation  of 
ceramidase  protein  (chapter  3.2)  [Franzen  et a/.  2002a].  This  depletion  is  completely 
prevented  by  pretreatment  of renal  mesangial  cells  with  lactacystin  (Fig.  32A)  in  a 
concentration-dependent manner (Fig.  328), thus confirming and extending our previous 
observations (Fig.  19, Fig. 26). To fully block the NO-mediated effect a concentration of 
10)JM  of lactacystin  is  required.  In  parallel,  neutral  ceramidase  activity  measurements 
reveal that the NO-mediated reduction of activity is also reverted by lactacystine (Fig. 33). 
A similar effect is obtained with c1asto-lactacystin  ~-Iactone [Dick et a/.  1997], which is the 
active metabolite of the natural product lactacystin (data not shown). Consistent with the 
observed  increase  of ceramidase  protein  and  activity  in  lactacystin-treated  mesangial 
cells, a decrease of NO-induced ceramide formation was found in the cells as analysed by 
mass spectrometry of extracted lipids (Fig. 34). 
To further confirm the degradation of ceramidase by the ubiquitin/proteasome complex in 
response to nitric oxide, a potential  ubiquitination of the enzyme in response to NO  was 
investigated.  For this  purpose  cells  were  pretreated  with  lactacystin  in  order to  block Figure 32 
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Effect ofIactacystin on NO~reduced  neutral ceramidase protein levels. 
(A):  Quiescent rat mesangial  ceHs  were stimulated for 24h with  either vehicle (control)  Of spennine-NO (in mM) in the absence  Of 
presence of  lactacystin (20p.Mj 2h pretreated). 
(B): Quiescent cells were pretreated for 2 h with the indicated concentrations of iactacystin (in J.1M) before stimulation with spermine-
NO (O.5mM) in the absence or presence of  the indicated concentrations of  lactacystin for 24 h. Thereafter, ce111ysates containing lOOJlg 
of protein were subjected to  SDS-PAGE  (7% acrylamide gel) and transfered  to nitrocellulose membrane.  Western  blot analysis was 
performed using an anti-neutral ceramidase antiserum at a dilution of  1  :500. Data are representative of2 independent experiments giving 
similar results 
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Effect oflactacystin on NO~reduced  neutral ceramidase activity. 
Quiescent rat mesangial cells were stimulated for 24h with either 
vehicle (control) or spennine-NO (SP-NO;  l.OmM) in the absence 
or presence of  the indicated concentrations ofiactacystin for 24h as 
indicated. 
CeIllysates containing 100Jlg of protein were taken  for a neutral 
ceramidase  activity  assay  as  described  in  chapter  2.6.1.1.  The 
generated  ct
4C]sphingosine  was  separated  on  thin  layer 
chromatography  and  evaluated  on  an  Imaging  System  (Fuji). 
Results are expressed as % of  control values and are means ±S.D. 
(n=4).  Neutral ceramidase activity in control cells was 24.0 ± 1.5 
pmoVm!¥h. 
degradation  and  thereafter  stimulated  for  various  time  periods  with  spermine-NO.  As 
shown in  Fig.  35A,  immunprecipitated ceramidase shows a time-dependent increase of 
ubiquitination when Western blot analysis was performed using an anti-ubiquitin antibody. 
Maximal ubiquitination occurs 30-120 minutes after treatment with spermine-NO. Similar 
data were obtained when cell extracts were subjected to immunoprecipitation with an anti-Results 
ubiquitin antibody followed by Western blot detection using the anti-ceramidase antibody 
(Fig. 358). 
Figure 34 
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Effect  of lactacystin  on  NO-induced  ceramide  formation  in 
mesangiai cens. 
Quiescent  cens  were pretreated  for  2 h with lactacystin  (20  !J.M) 
before stimulation  with  spennine-NO  (l.Omh1)  in  the  absence or 
presence of the  indicated  concentrations  of iactacystin  for  24  h. 
Thereafter,  lipids  were  extracted  and  ceramide  was  analysed  by 
LClMSlMS  spectrometry  as  described  under  2.6.2.  Results  are 
means ± S.D. (n-4). 
The availability of the signalling molecule ceramide is fine tuned by the rate of generation 
involving sphingomyelinases and de-novo synthesis and the rate of degradation catalysed 
by ceramidases [Huwiler et al. 2000]. Whereas, sphingomyelinases have attracted interest 
due to their immediate regulation by an increasing list of stimuli like vitamin 0 3, UV light, 1-
irradiation,  Fas ligand  or doxorubicin,  more recently,  the  neutral ceramidase  has turned 
out  to  be  a  key  enzyme  in  the  regulation  of intracellular free  ceramide  concentration 
particularly in  response to the stress mediator NO and  NO-inducing cytokines [Nikolova-
Karakashian et al.  1997, Huwiler et al.  1999a, Huwiler et al.  1999b, Huwiler et al. 2001]. In 
terms  of neutral  ceramidase  regUlation,  NO  was  found  to  inhibit  neutral  ceramidase 
activity in mesangial cells [Huwiler et al.  1999b]. This effect is due to down-regulation of 
the protein by increased degradation [Franzen et al.  2002a].  In this study, it is show that 
the  degradation  of neutral  ceramidase  by  NO  depends  on  the  ubiquitin/proteasome 
pathway.  Activation  of the  proteasome  is  a  well  known,  fundamental  mechanism  for 
protein turnover, cell cycle control and  signal transduction [Hershko & Ciechander 1998]. 
Conceptually, proteolysis by the ubiquitin/proteasome system is considered  to  comprise 
three  steps:  identification  of the  protein  to  be  degraded,  marking  of that  protein  by 
attachment  of  ubiquitin  to  lysine  residues,  and  delivering  it  to  the  proteasome,  a 
multienzyme  protease  complex  specific  for multiubiquitinated  substrates  [Pickart 2001] 
that  will  degrade  it  and  recycle  ubiquitin.  How  NO  is  mechanistically  activating  the 
proteasome system is presently unknown.  In principle, NO can mediate, especially under 
inflammatory  conditions  when  also  large  amounts  of  reactive  oxygen  species  are 
generated,  protein  nitration,  nitrosation  and  oxidation.  In  addition,  it  can  form  nitrosyl 
complexes with metalloproteins [Pfeilschifter et al. 2001 aJ. Results 
It  could  be  speculated  that  one  ubiquitinating  enzyme  or  a  component  of the  26  S 
proteasome  complex  is  modified  at  a  critical  site  by  NO.  Alternatively,  it  is  possible 
Figure 35 
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NO induces ubiquitination of  neutral ceramidase in mesangial cells. 
Quiescent mesangial cells were pretreated for 2 h with 20!J.M lactacystin and then left untreated (control) or treated with 1  mM spennine~ 
NO  (SP~NO) for the indicated time periods (in hours).  Thereafter,  cells  were lysed  and processed for immunoprecipitation by using 
either  a polyclonal  antibody  against  neutral  ceramidase  followed  by  Western  blot  analysis  with  an  anti-ubiquitin  antibody  (A)  or 
immunoprecipitated with the anti-ubiquitin antibody followed by Western blot analysis with neutral cerarnidase antibody (B). Data are 
representative of2 independent experiments giving similar results. 
that  NO  stimulation  leads  to  nitration  or nitrosation  of neutral  ceramidase  itself,  which 
subsequently  may  facilitate  faster  degradation  of  the  enzyme  by  the 
ubiquitine/proteasome system.  In  this  context,  it is  interesting  to  note that Souza  et a/. 
[2000] reported an increased degradation of nitrated proteins by the proteasome and thus 
guarantees the removal of nitrated proteins in vivo.  Furthermore, others have shown that 
oxidative stress leading to  the  generation of peroxynitrite,  increases the  degradation of 
various  proteins,  including  aconitase  by  the  proteasome  pathway [Grune  et a/.  1998]. 
Peroxynitrite  is  thought  to  cause  nitration  of  target  proteins  at  tyrosine  residues 
[Pfeilschifter et al. 2001 b]. Results 
A proposed activation of the  proteasome by NO,  as  suggested  by our data from  renal 
mesangial cells and other studies in  K562 leukemia cells and pheochromocytoma PC  12 
cells, is contrasted by the finding that in the mouse macrophage cell line RAW 264.7 NO 
inhibited  the  proteasome  [Glockzin  et  al.  1999].  That  study  showed  that  lactacystin 
mimicked  the  effect  of  NO  to  induce  accumulation  of  the  tumor  suppressor  p53. 
Furthermore, NO was shown to trigger deubiquitination of p53. 
However,  it  is  worth  noting  that  RAW  264.7  macrophages  and  renal  mesanglal  cells 
respond  differentially to  NO  stimulation  most likely due  to  their  different capacities  to 
handle  reactive  nitrogen  and  oxygen  species  determined  by  differences  in  their 
glutathione redox system [Sandau et al.  1998, Pautz et al.  2002, Sumbayev et al. 2002]. 
Thus macrophages and endothelial cells are very sensitive to endogenous NO production 
and  readily  undergo apoptosis  after stimulation  with  tumour necrosis factor a  (TNF-a) 
[Manderscheid  et al.  2001],  whereas  mesangial  cells  are  completely resistant to  TN Fa 
stimulation,  although  endogenous  NO  production  takes  place.  This  mesangial  cell 
protection correlates with high levels of reduced glutathione and high levels of inhibitor of 
apoptosis (lAP) protein levels [Manderscheid et al. 2001]. 
By sequence analysis of neutral ceramidase, several lysine residues as necessary targets 
for ubiquitin  attachment can  be found  in  the  primary sequence [Mitsutake et al.  2001]. 
Further obvious sequence characteristics like a destruction box (0 box) composed of the 
sequence R-X-X-L-X-X-X-X-N found in the N-terminus of proteins [Glotzner et al.  1991] or 
a KEN box composed of the sequence K-E-N-X-X-X-N/O located in the N or C terminus of 
the proteins [Pfleger & Kirschner 2000] which are targets for one special class of ubiquitin 
ligase, the  anaphase  promoting  complex  are  missing.  However,  several other ubiquitin 
ligase complexes have been identified. 
Further studies are required to characterise the involved ligase complex in more detail. 
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3.4  PKC-dependent translocation of neutral ceramidase to the nuclear membrane 
Introduction 
The  green  fluorescent  protein  (GFP)  isolated  from  the  Pacific jellyfish,  Aequoria  victoria 
[Morin  &  Hastings  1971]  was  been  shown  to  transduce,  by  energy  transfer,  the  blue 
chemiluminescence  of  another  protein,  aequorin,  into  green  fluorescent  light  [Ward  & 
Cormier  1979].  The  molecular  cloning  of  GFP  cDNA  [Prasher  et  al.  1992]  and  the 
demonstration by Chalfie et al. that GFP can be expressed as a functional transgene [Chalfie 
et al.  1994] have opened  exciting  new avenues of investigation in cell,  developmental and 
molecular biology. GFP has been used as a fluorescent reporter molecule in the localisation 
of membrane receptors, cytoplasmic proteins,  and secretory proteins. In  the  present study, 
we report on the development of a green fluorescent protein conjugated neutral ceramidase 
(GFP-NCER) to study neutral ceramidase translocation in response to stimulation with  PKC 
activators like the phorbol ester TPA. 
Results 
Characterisation of  neutral ceramidase-GFP (NCER-GFP) fusion protein 
In order to investigate the cellular localisation of neutral ceramidase in living cells, a plasmid 
was  constructed  encoding  GFP-tagged  neutral  ceramidase  fusion  protein.  The  cDNA 
construct  of GFP-tagged  neutral  ceramidase  was  confirmed  by  sequencing.  Transient 
transfection experiments with the human embryonic kidney cell  line 293 (HEK 293) lead to 
overexpression  of the fusion  protein which  was  confirmed  by Western blot analysis of cell 
extracts  as  seen  in  Fig.  35A.  NCER-GFP was  recognised  as  a double  band  at  140 kDa 
corresponding  well  to the  calculated  mass of the cDNA complex and to previous Western 
blot results of neutral ceramidase which also detected two bands (chapter 3.1). Furthermore, 
Iysates  containing  overexpressed  NCER-GFP  protein  displayed  more  than  10.000-fold 
increased  ceramidase  activity compared  to  vector control  (Fig.  358) indicating  that GFP-
tagged neutral ceramidase was a functionally active fusion protein. 
Localisation of  neutral ceramidase-GFP 
HEK 293  cells  were  transiently transfected  for 24h  with  neutral  ceramidase-GFP  or GFP 
alone,  respectively,  and  thereafter  viewed  by confocal  microscopy.  As  seen  in  Fig.  36, 
unstimulated cells showed a staining of the cytoplasm with a characteristic accumulation in a 
perinuclear  region.  HEK  293  cells  expressing  only  the  GFP  protein  show  fluorescence 
throughout the cell including the nucleus (data not shown). To identify the perinuclear region 
in which NCER-GFP accumulated, colocalisation studies were performed using MitoTracker® 
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Orange  CMTMRos  as  useful  tool  to stain  mitochondria  and  an  antibody directed  against 
GM130 as a specific Golgi complex marker. 
Overlapping images demonstrate that NCER-GFP was not localised in mitochondria but the 
perinuclear region was stained by NCER-GFP as well as by the GM130 antibody indicating a 
possible partial localisation of neutral ceramidase in the Golgi complex (Fig. 37A and 37B). 
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Expression (A) and activity (B) of  neutral ceramidase-GFP fusion protein in HEK293 cells. 
HEK 293 cens  were transfected with pEGFP-NI  vector containing neutral  ceramidase-GFP or with empty vector as  described  in chapter 
2.2.2. Thereafter, cell lysates containing  lOOllg  of protein were taken for SOS-PAGE  (7% acrylamide gel) and subsequent Western blot 
analysis using a specific anti-GFP antibody at a dilution of 1:1000 (A) or a neutral ceramidase activity assay (B) as described in chapters 
2.5.6. and 2.6.1.1. The generated [14C]sphingosine was separated on thin layer chromatography and evaluated on an Imaging System (Fuji). 
Data in A are representative of aJ least 2 independent experiments giving similar results. Results in B are expressed as % of control values 
and are means ±S.D. (n=3-4). 
PKC dependent translocation of  neutral ceramidase-GFP 
In a next step, transient transfected HEK 293 cells by NCER-GFP were stimulated with the 
PKC  activator  TPA  followed  by  confocal  microscopy  (5  minute  intervals).  Upon  TPA 
stimulation, GFP-tagged neutral ceramidase translocated to the nuclear membrane. This was 
first  detectable  after  10  minutes  by  using  25nM  TPA  (data  not  shown)  and  reached  a 
maximum after 45 minutes (Fig. 38). Results 
Figure 36 
Localisation of  neutral ceramidase-GFP fusion protein in HEK 293 cells. 
HEK 293 cells were transfected with pEGFP-NI vector containing neutral ceramidase-GFP or with empty vector as described in chapter 
2.2.2. Thereafter, cells were viewed by confocal microscopy as described under 2.7, 
Figure 38 
control 
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Translocation ofneutraJ ceramidase-GFP fusion protein by stimulation ofPKC in HEK 293 cells. 
HEK 293 cells were transfected with pEGFP-NI vector containing neutral ceramidase-GFP as described in chapter 2.2.2. Thereafter, cells 
were stimulated with vehicle (control) or 25nM TPA and viewed by confocal microscopy every 5 minutes up to one hour stimu1ation as 
described under 2.7. 
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Localisation of  neutral ceramidase-GFP fusion protein in HEK 293 cells. 
Results 
Overlap 
Overlap 
HEK293 cells were traItsfected with pEGFP-Nl vector containing neutral ceramidase-GFP as described in chapter 2.2.2. Thereafter, cells 
were  treated  either  with  MitoTracker®  Orange CMfMRos (2S0nM)  or ftxed  (2.7)  and  afterwards  incubated with  GMJ30 antibody. 
Finally, living and fixed cells were viewed by confocal microscopy as described lUlder 2.7. 
c 
Neutral ceramidase  Goigi complex  Overlap 
Localisation of  neutral ceramidase in rat rnesangial cells. 
Mesangial cells cells fixed and incubated with a mix of  neutral ceramidase antibody (2.5.7) and GM130 antibody as described in chapter 
2.7. Fixed cells were viewed by confocal microscopy as described under 2.7. 
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Discussion 
In this part of the thesis the cellular localisation of neutral ceramidase was investigated using 
green  fluorescent  protein  (GFP)  as  fusion  protein  which  is  a  well  established  model  to 
examine cellular distribution and translocation of proteins. 
Unstimulated  HEK  293  cells  reveal  after  transient  transfection  experiments  that  neutral 
ceramidase is  preferentially localised in the cytoplasm.  A similar cytoplasmic localisation is 
also seen  in rat mesangial cells. PKC activation leads to a striking accumulation of neutral 
ceramidase at the nuclear membrane. 
A recent study showed that neutral as well as acid ceramidase activities are actively secreted 
by murine endothelial cells, RAW 264.7 murine macrophages and IMR-90 human fibroblasts. 
However, no further biochemical identification of the secreted enzymes was provided [Romiti 
et al.  2000a]. The exact distribution of neutral ceramidase  remained  unclear.  Furthermore, 
Romiti et al.  [2000a] reported  that the release of ceramidases is inhibited by brefeldin A,  a 
known inhibitor of secretion from the Golgi network [Orci et al.  1991, Rosa et al.  1992]. The 
release of neutral ceramidase was further potentiated by bradykinin and 12-0-tetradecanoyl-
phorbol-13-acetate (TPA) strongly indicating the implication of PKC activation in secretion of 
neutral  ceramidase.  The  present  study,  however,  did  not  show  neutral  ceramidase 
translocation to the plasma membrane but rather to the nuclear membrane in HEK 293 cells 
after  PKC  activation  (Fig.  38)  pointing  towards  a  cell  type  specific  regulation  of neutral 
ceramidase trafficking. It remains to be shown whether neutral ceramidase is also secreted 
by TPA treatment of HEK 293 and rat mesangial cells. 
Interestingly,  acid  sphingomyelinase  was  also  shown  to  be  secreted,  either constitutively 
[Hurwitz et al.  1994, Schissel et al.  1998] or after platelet activation [Romiti et al.  2000b] or 
cytokine  exposure  [Marathe  et al.  1998]  suggesting  agonist-regulated  mechanisms.  The 
concomitant release of sphingomyelinases and  ceramidases combined  with  recent findings 
of PKC-dependent activation, translocation and secretion of sphingosine kinase [Johnson et 
al.  2002]  suggest  that,  besides  sphingolipid  action  as  second  messenger  in  signalling 
cascades,  additional  important  roles  as  autocrine/paracrine  signalling  molecules.  This  is 
further corroborated by the existence of sphingosine-1-phosphate receptors on the surface of 
endothelial  cells and their potential to evoke biological activity like differentiation, migration 
and mitogenesis [Hla 2001, Mandala et al. 2002]. 
Nevertheless, the findings of this study support also the  important role  of sphingolipids as 
signalling  molecules  inside  the  cell.  In  view  of the  reported  lack  of increase  in  neutral 
ceramidase activity upon TPA stimulation [Franzen et al.  2002a],  it is tempting to speculate 
that  phosphorylation  of neutral  ceramidase  and  subsequent  translocation  to  the  nuclear 
membrane protects  the  enzyme from  degradation triggered  by nitric oxide  [Franzen  et al. 
2002a].  Several  studies  reported  on  nuclear  localisation  of a  neutral  sphingomyelinase Results 
[Alessenko & Chatterjee  1995, Jaffrezou et al.  2001,  Mizutani et al.  2001] thus giving hints 
for an  important role  of the  nuclear region  in  sphingolipid-mediated  signalling  and  thereby 
reinforcing the putative function of neutral ceramidase translocation to the nuclear membrane 
as shown in this chapter. 
In  summary,  this part has shown  that neutral ceramidase  is  localised in  the  cytoplasm  of 
unstimulated HEK 293 and rat mesangial cells. Upon TPA stimulation a translocation to the 
nuclear  membrane  is  found  which  may  point  to  an  additional  functional  role  of  neutral 
ceramidase at the cell nucleus. Discussion 
4 SUMMARIZING DISCUSSION 
4.1  Regulation of ceramidases 
Among  the  different  pathways  regulating  ceramide  formation  this  thesis  focused  on 
ceramide  degrading  enzymes:  the  ceramidases.  This  class  of enzymes  regulated  the 
hydrolysis  of ceramide  to sphingosine  which  is a substrate for the  sphingosine  kinase 
yielding sphingosine-1-phosphate, a potent mitogen for various cells. 
In  a  first  part  of  the  study  the  effect  of  the  pro-inflammatory  cytokine  IL-1~  was 
investigated.  IL-1~ leads  to  activation  of neutral  ceramidase  activity  which  is  due  to 
transcriptional  and  translational  upregulation  [Franzen  et  al.  2001].  Mechanistically this 
upregulation of neutral ceramidase by  IL-1~ involves the stress-activated protein kinase 
p38-MAPK,  since  a  specific  inhibitor  of  this  kinase  efficiently  blocked  the  protein 
upregulation as  well  as  activity. Consistently, increased intracellular ceramide levels are 
measured  upon  IL-1~  stimulation  in  the  presence  of S8  202190  which  leads  to  an 
increased  rate  of apoptosis.  Among  the  different  downstream  targets  of p38  MAPK, 
MAPKAP-K-2  could  be  excluded  as  a  mediator  of the  described  neutral  ceramidase 
activation  by using  mesangial  cells  from  MAPKAP-K-2  knockout mice  [Kotlyarov et al. 
1999]. 
Furthermore, the results clearly show that the stimulation with  IL-1~ delivered a maximal 
activation  of the  neutral  ceramidase  after 4  to  5  hours  of stimulation  which  thereafter 
declines again (Fig. 6A). This delayed regulation is due to the expression of the inducible 
nitric oxide synthase (iN OS) by  IL-1~ followed by the production of high concentrations of 
nitric oxide which in turn trigger proteolytic.degradation of neutral ceramidase as shown by 
co-stimulation with the nitric oxide synthase (NOS)-inhibitor L-NMMA which prevents the 
decline of neutral ceramidase activity (Fig. 6C). 
Molecular cloning and sequence analysis has revealed the existence of three distinct NOS 
isotypes that are either constitutively expressed in endothelial cells (eNOS) and neurones 
(nNOS) or are inducible (iNOS) by endotoxin and by inflammatory cytokines such as IL-1 
and TNFa in macrophages and many other cell types [Moncada & Palmer 1991; Nathan & 
Xie 1994]. For example,  IL-1~ is a strong stimulus for iNOS transcription in rat mesangial 
cells [Pfeilschifter & Schwarzenbach 1990, Kunz et al.  1994]. iNOS requires a delay of 6-
8 h before the onset of NO production but, once induced, this enzyme is active for hours 
to  days and  produces  NO  in  1000-fold  larger quantities than  the  constitutive  enzymes 
eNOS  and  nNOS. At low concentrations,  NO  stimulates guanylate cyclase activity and 
triggers  the  formation  of  cyclic  GMP  (cGMP),  an  important  messenger  mediating 
physiological functions of NO such as vascular homeostasis. Higher concentrations of NO 
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produced  by iNOS  interact with  thiol  groups or transition  metal-containing  proteins and 
can alter protein function or initiate gene expression to protect cells. There is a continuous 
shift at even  higher concentrations of NO towards cell  damage or apoptosis, with  other 
factors in  the microenvironment of a cell critically influencing the final outcome [Brune et 
al.1998]. 
This activation of iNOS by IL-1~ in rat mesangial cells is well compatible with the second 
part of this thesis dealing with the down-regulation of neutral ceramidase by nitric oxide 
[Franzen  et  al.  2002a].  Exposure  to  high  concentrations  of nitric  oxide  leads  to  a 
significant decrease of neutral ceramidase activity and protein in mesangial cells [Huwiler 
et al.  1999b,  Franzen et al.  2002a] which could,  at least partially, explain the observed 
counter-regulation after long-term stimulation with  IL-1~. 
NO was found to increase ceramide levels in  the cell by a dual mechanism: on the one 
hand it stimulates the ceramide producing enzymes acid and neutral sphingomyelinases, 
thus leading to an increased ceramide formation,  and on the other hand NO inhibits the 
ceramide degrading enzymes, the acidic and neutral ceramidases, and thereby results in 
an amplified increase in ceramide steady-state levels [Huwiler et al.  1999b]. By contrast, 
pro-inflammatory  cytokines  like  TNFa  and  IL-1~,  besides  activating  the 
sphingomyelinases  cause  a  potent  activation  of  the  ceramidases,  which  fully 
compensates for the increased generation of ceramide [Huwiler et al.  1999b, Franzen et 
al.  2001].  This may also  explain  why  mesangial  cells  undergo  apoptosis  when  NO  is 
delivered  by exogenous sources  but  are  resistant to endogenously produced  NO  after 
cytokine-induced  inducible  NOS  expression  [MOhl  et al.  1996,  Pfeilschifter &  Huwiler 
1996,  Nitsch et al.  1997, Franzen et al.  2001]. The NO-mediated inhibition of ceramide-
degrading enzymes was further investigated and found to be due to degradation of neutral 
ceramidase protein [Franzen et al.  2002a]. Mechanistically, this degradation is mediated 
by the ubiquitin/proteasome complex in renal mesangial cells as shown in the third part of 
this studies [Franzen et al. 2002b]. 
The NO-induced degradation of neutral ceramidase can  be reversed by PKC activating 
agents,  like the phorbol ester TPA, but also the physiologically important ligands PDGF-
BB, angiotensin II  and ATP. As found in in vitro and  in vivo phosphorylation experiments 
PKC-o is able to phosphorylate neutral ceramidase and appears to be the prime candidate 
for exerting the anti-apoptotic action in mesangial cells by stabilising neutral ceramidase. 
It is well established that activation of protein kinase C,  either directly or indirectly, could 
regulate the level of proteins by posttranslational mechanisms. One possible way of action 
may  be  phosphorylation  of components  of the  ubiquitin/proteasome  machinery.  In  the 
case of growth arrest and  DNA-damage-inducible gene (Gadd45) the deubiquitination is 
PKC-o dependent [Leung et al.  2001] which offers an  obvious link to the degradation of Discussion 
neutral ceramidase. Therefore it is tempting to speculate on two different mechanisms by 
which  PKC  activation  could  be  connected  with  neutral  ceramidase  stability  and 
subsequent  improved  elimination  of ceramide  which  in  turn  may protect the  cell  from 
apoptosis:  (i)  direct  phosphorylation  of  neutral  ceramidase  leading  to  changes  in 
conformation  and  enzymatic  accessibility,  its  cellular  transport  and  subsequent 
localisation,  and  (ii)  phosphorylation  of enzymes  of the  ubiquitin/proteasome  pathway 
causing  altered  ubiquitination either by inhibition of ubiquitin-conjugating enzymes or by 
activation ofdeubiquitinating enzymes. 
Furthermore, cytokine-induced activation of neutral SMase was inhibited by stimulation of 
PKC  by  TPA  with  subsequently  reduced  formation  of ceramide  [Kaszkin  et al.  1998], 
indicating that PKC acts at least at two different levels to prevent ceramide accumulation 
and  subsequent  apoptosis,  i.e.  at  the  level  of sphingomyelinase,  and  at  the  level  of 
ceramidase. 
In the last part of the thesis the localisation of neutral ceramidase was investigated using 
green fluorescent protein as tool to visualise proteins of interest inside the cell. Referring 
to transfection experiments with GFP-tagged neutral ceramidase and subsequent staining 
of cellular compartments  neutral  ceramidase seemed  to be  preferentially located  in  the 
cytoplasm  of unstimulated  cells.  This distribution changed  upon  PKC  activation  by TPA 
leading to a striking accumulation of neutral ceramidase at the nuclear membrane. 
4.2  Clinical relevance 
With  regard  to  the  known  properties  of the  different  components  of the  sphingolipid 
network  in  tissue  physiology  and  pathophysiology,  several  strategies  to  get  useful 
therapeutic  approaches  for  a  variety  of diseases  have  been  developed.  Elevation  of 
cellular ceramide is being  used for therapies aiming to  arrest cell  growth  or to promote 
apoptosis.  Conversely,  agents  that  reduce  ceramide  or raise  sphingosine-1-phosphate 
tend to attenuate apoptosis and support proliferation. 
It  was  shown  that  ceramide-coated  balloon  catheters  significantly  reduced  neointimal 
hyperplasia induced by balloon angioplasty in rabbit carotid arteries in vivo. This ceramide 
treatment decreased the number of vascular smooth muscle cells entering the cell cycle 
without inducing apoptosis [Charles et al.  2000] pointing out the benefit of cell-permeable 
ceramide as novel therapy for reducing neointimal hyperplasia after balloon angioplasty. 
Secondly,  exogenously  applied  ceramide  augmented  paclitaxel-induced  apoptosis  in 
human  Tu138  head  and  neck  squamous  carcinoma  cell  line  in  vitro  when  added  in 
combination  with  paclitaxel  [Mehta  et al.  2000]  indicating  effectiveness of ceramide  in 
cancer therapy. This was corroborated by the study of Selzner et al. [2001] demonstrating 
that human  colon  cancer showed  a more than  50%  decrease in  the  cellular content of Discussion 
ceramide when  compared with healthy colon mucosa. Application of ceramide analogues 
and  ceramidase  inhibitors  induced  rapid  cell  death  through  activation  of  various 
proapoptotic  molecules,  such  as  caspases  and  release  of cytochrome  c.  Ceramidase 
inhibition increases the ceramide content of tumour cells, resulting in maximum activation 
of the apoptotic cascade. Importantly, normal cells were completely resistant to inhibitors 
of ceramidases.  Treatment of nude mice with  B13, the most potent ceramidase inhibitor, 
completely prevented tumour growth using two different aggressive human colon cancer 
cell  lines.  Therefore,  B13  and  related  analogues  of  ceramide  and  inhibitors  of 
ceramidases  offer  a  promissing  therapeutic  strategy  with  selective  toxicity  towards 
malignant but  not normal  cells [Selzner et aJ.  2001].  Moreover,  safingol,  a sphingosine 
kinase  inhibitor  that  prevents  formation  of  sphingosine-1-phosphate  from  degraded 
ceramide, combined with fenretinide, which was reported to increase ceramide generation 
via the de novo pathway [Maurer et al. 2000, Wang et a/.  2001], synergistically enhanced 
cytotoxicity in  various tumour cell lines [Maurer et al.  2000].  Hence, safingol was already 
used in a phase I clinical trial without dose-limiting toxicity [Schwartz et a/.  1997]. 
On  the  other  hand,  blocking  ceramide  formation  or  manipulation  of  sphingosine-1-
phosphate  levels,  respectively,  may also be  of therapeutic utility and  protect from  side 
effects of cancer treatment.  For example,  genetic inactivation of acid  sphingomyelinase 
(A-Smase)  prevented  microvasculature  endothelial  cells  of  the  small  intestine  from 
apoptotic damage [Paris  et al.  2001].  Furthermore,  it was  shown  that female A-Smase 
knock  out  mice  suppressed  the  normal  apoptotic  deletion  of fetal  oocytes,  leading  to 
neonatal  ovarian  hyperplasia [Morita  et a/.  2000].  Ex  vivo,  oocytes lacking the gene for 
acid  sphingomyelinase  or  wild-type  oocytes  treated  with  sphingosine-1-phosphate 
resisted physiological apoptosis and apoptosis induced by anti-cancer therapy. Moreover, 
radiation-induced  oocyte  loss  in  adult  wild-type  female  mice,  the  event  that  drives 
premature  ovarian  failure  and  infertility  in  female  cancer  patients,  was  completely 
prevented by in vivo therapy with sphingosine-1-phosphate [Morita et a/.  2001,  Spiegel & 
Kolesnick  2002].  Thus,  the  sphingomyelin  pathway  and  especially  sphingosine-1-
phosphate represent a new target to preserve ovarian function upon cancer therapy. 
Additionally,  sphingosine-1-phosphate  and  structural  analogues  like  FTY720  revealed 
immunosuppressive  qualities  through  altered  lymphocyte  trafficking  mediated  by 
activation  of sphingosine-1-phosphate receptors  [Brinkmann  et al.  2001,  Mandala  et  al. 
2002].  Both species were high-affinity agonists of at least four of the five S1 Preceptors. 
These agonists produce lymphopenia in  blood  and  thoracic duct lymph by sequestration 
of lymphocytes  in  lymph  nodes.  S1P  receptor  agonists  induced  emptying  of lymphoid 
sinuses by retention of lymphocytes and inhibition of outlet into lymph. Thus, inhibition of 
lymphocyte recirculation by activation of S  1  P receptors may result in therapeutically useful Discussion 
immunosuppression [Mandala  et al.  2002] which  has already been  applied  successfully 
for FTY720 in clinical trials in renal transplant patients [Brinkmann et al. 2001]. 
Taken together, the sphingolipid network provides several compounds and enzymes to be 
targeted  in  a pharmacological  reasonable  way.  Especially the  ceramidases,  as  "power 
button" in  the regulation of ceramide and sphingosine-1-phosphate being key opponents 
in  the  balance  of  cell  death  and  survival,  provide  the  opportunity  to  interfere  in 
pathophysiology in general, particularly with regard to cancer therapy. 
Concerning  the  results  of this  thesis,  it  could  be  demonstrated  that  several  ways  of 
interference  with  the  regulation  of  ceramidases  do  exist.  Physiological  or 
pathophysiological stimuli like the  pro-inflammatory cytokine  IL-1~ and  nitric oxide were 
shown  to  alter  ceramidase  activity  in  mesangial  cells.  IL-1~  led  to  an  increase  of 
ceramidase  activity  [Franzen  et al.  2001]  whereas  nitric  oxide  was  able  to  decrease 
ceramidase  activity  through  the  ubiquitin/proteasome  pathway  [Franzen  et al.  2002a, 
2002b]. Both events subsequently impact on cellular biology. 
In  summary,  the  neutral  ceramidase  represents  an  attractive  target  enzyme  for novel 
therapeutic approaches in the treatment of inflammatory diseases and tumour growth. 
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5 SUMMARY 
During the past several years, ceramide has emerged as an important second messenger 
triggering  cell  responses  including  proliferation,  differentiation,  growth  arrest  and 
apoptosis. This thesis has focused on the regulation of neutral ceramidase which critically 
determines,  in  concert  with  ceramide  generating  sphingomyelinases,  the  intracellular 
ceramide levels. 
In  the  first  part  it  is  reported  that  besides  a  rapid  and  transient  increase  in  neutral 
sphingomyelinase activity a second  delayed peak of activation  occurs  after hours of IL-
1  ~ treatment. This second phase of activation is first detectable after 2 h of treatment, and 
steadily increases over the next two hours reaching maximal values after 4 h. In parallel, a 
pronounced  increase  in  neutral  ceramidase  activity  is  observed,  which  accounts  for a 
constant or even  decreased  level of  ceramide after long-term  IL-1~ treatment, despite 
continuous sphingomyelinase activation. 
The  increase  in  neutral  ceramidase  activity  is  due  to  expressional  up-regUlation,  as 
detected  by  an  increase  in  mRNA level  and  enhanced  de  novo protein  synthesis.  The 
increase  of  neutral  ceramidase  protein  levels  and  activity  can  be  blocked  dose-
dependently  by  the  p38- mitogen-activated  protein  kinase  (p38-MAPK)  inhibitor,  SB 
202190,  whereas the classical MAPK pathway inhibitor U0126,  and the PKC inhibitor Ro 
31-8220  were  ineffective.  Moreover,  co-treatment  of cells  for 24  h with  IL-1~ and  SB 
202190 leads to an increase in ceramide formation. Interestingly,  IL-1~-stimulated neutral 
ceramidase  activation  is  not  reduced  in  mesangial  cells  isolated  from  mice  deficient in 
MAPK-activated  protein  kinase  2  (MAPKAPK-2),  which  is  one  possible  downstream 
substrate  of the p38-MAPK,  thus suggesting  that the  p38-MAPK-mediated  induction  of 
neutral ceramidase occurs independently of MAPKAPK-2. 
The results suggest a biphasic regulation of sphingomyelin hydrolysis in cytokine-treated 
mesangial  cells  with  a delayed  de  novo synthesis  of neutral  ceramidase  counteracting 
sphingomyelinase activity and apoptosis. Neutral ceramidase may thus represent a novel 
cytoprotective enzyme for mesangial cells exposed to inflammatory stress conditions. 
In a second part, the effect of NO on neutral ceramidase was studied. Ceramide levels are 
strongly increased in  a delayed fashion  by stimulation of renal  mesangial cells with  NO. 
This effect is due to a dual action of NO,  comprising an activation of sphingomyelinases 
and  an  inhibition  of ceramidase  activity.  The  inhibition  of neutral  ceramidase  activity 
correlates  with  the  decrease of neutral  ceramidase  protein.  A complete  loss  of neutral 
ceramidase  protein  is  obtained  after 24h  of NO  stimUlation.  Moreover, the  NO-induced 
degradation  is  reversed  by  the  protein  kinase  C  (PKC)  activator,  12-0-Summary 
tetradecanoylphorbol-13-acetate  (TPA) ,  but  also  by  the  physiological  PKC  activators 
platelet-derived  growth  factor-BB  (PDGF-BB),  angiotensin  II  and  ATP,  resulting  in  a 
normalisation of neutral ceramidase protein as well as activity. 
In  vivo  phosphorylation  studies  using  32Pj_labelled  mesangial  cells,  reveal  that  TPA, 
PDGF-BB,  angiotensin  II  and  ATP  trigger an  increased  phosphorylation  of the  neutral 
ceramidase, which is blocked by the broad-spectrum PKC inhibitor Ro-31  8220, but not by 
CGP  41251,  which  has  a  preferential  action  on  Ca2 +-dependent  PKC  isoforms,  thus 
suggesting  the  involvement  of  a  Ca2 +-independent  PKC  isoenzyme.  In  vitro 
phosphorylation  assays  using  recombinant  PKC  isoenzymes  and  neutral  ceramidase 
immunoprecipitated  from  unstimulated  mesangial  cells,  show that particularly the  PKC-
/l isoform,  and  to  a  lesser  extent  the  PKC-a isoform,  are  efficient  in  directly 
phosphorylating neutral ceramidase. 
The  data  show  that  NO  is  able  to  induce  degradation  of neutral  ceramidase  thereby 
promoting accumulation of ceramide in the cell. This effect is reversed by PKC activation, 
most probably by the  PKC-/l isoenzyme,  which  may directly phosphorylate and  thereby, 
prevent neutral ceramidase degradation. 
In  the  third  chapter  it  is  demonstrated  that  the  NO-triggered  degradation  of neutral 
ceramidase  involves  activation  of  the  ubiquitin/proteasome  complex.  The  specific 
proteasome  inhibitor,  lactacystin,  completely  reverses  the  NO-induced  degradation  of 
ceramidase  protein  and  neutral  ceramidase  activity.  As  a  consequence,  the  cellular 
amount  of ceramide,  which  drastically increases  by  NO  stimulation,  is  reduced  in  the 
presence of lactacystin. Furthermore, ubiquitinated neutral ceramidase accumulates after 
NO  stimulation., The  data  clearly  show  that  the  ubiquitin/proteasome  complex  is  an 
important determinant of neutral ceramidase activity and thereby regulates the availability 
of ceramide. 
In a last part, the cellular localisation of neutral ceramidase was investigated using green 
fluorescent  protein  (GFP)  as  fusion  protein  to  examine  cellular  distribution  and 
translocation  of neutral  ceramidase.  Unstimulated  HEK 293  cells  reveal  after transient 
transfection  experiments  that  neutral  ceramidase  is  preferentially  localized  in  the 
cytoplasm.  PKC  activation  led  to  an  accumulation  of neutral  ceramidase  at the  nuclear 
membrane. 
In  summary,  this  work  demonstrates  that  the  neutral  ceramidase  is  a  fine  regulated 
protein that plays a critical role in regulating intracellular ceramide levels and thereby the 
cell's  fate  to  undergo  apoptosis  or survive.  Regulation  of neutral  ceramidase  can  be 
achieved  on  all levels, i.e.  on  the mRNA level, the  protein level or posttranslationally by 
phosphorylation and subcellular translocation. Summary 
Future work will reveal whether neutral ceramidase can serve as  a therapeutic target in 
the development of novel antiinflammatory and anti-tumour drugs. 
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7.1  Abbreviations 
AC  acid ceramidase 
AP-1  activator protein 1 
A-SMase 
AT II 
ATF2 
ATP 
BSA 
CAPP 
cdk 
cGMP 
DG 
DMEM 
ECl 
eNOS 
ER 
ERK 
FAN 
FCS 
FD 
GADD 
GFP 
HEK 
IFNy 
Il  1~ 
iNOS 
IPa 
I1(B 
JNK 
lB 
lDl 
MAPK 
MAPKAPK 
MBP 
MEF2C 
MRM 
MS 
MSK 
NCER 
NF 
nNOS 
acid sphingomyelinase 
Angiotensin II 
activator of transcription 2 
adenosine triphosphate 
bovine serume albumin 
ceramide-activated protein phosphatase 
cyclin dependent kinase 
cyclic guanosine monophosphate 
diacylglycerol 
Dulbecco's Modified Eagles Media 
enhanced chemiluminescence 
endothelial nitric oxide synthase 
endoplasmatic reticulum 
extracellular signal regulated kinase 
factor associated with neutral sphingomyelinase 
fetal calf serume 
farber disease 
growth arrest and DNA-damage 
green fluorescent protein 
human embryonic kidney 
interferon y 
interleukin 1  ~ 
inducible nitric oxide synthase 
inositol-1,4,5-trisphosphate 
inhibitor of 1(B 
c-Jun-N-terminal kinase 
lauria-Bertani 
low density lipoprotein 
mitogen activated protein kinase 
mitogen activated protein kinase activated protein kinase 
myelin basic protein 
mouse embryonic factor 2C 
mutiple reaction monitoring 
mass spectrometry 
m~ogen- and stress-activated kinase 
neutral ceramidase 
nuclear factor 
neuronal nitric oxide synthase 
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R5 NO 
NSD 
N-SMase 
OD 
PA 
PAGE 
PBS 
PC 
PDGF 
PI 
PI3K 
PIP2 
PKB 
PKC 
PLA2 
PLC 
PLD 
Rb 
RPMI 
S1P 
SAP 
SAPK 
SM 
TLC 
TNFa 
TPA 
nitric oxide 
neutral sphingomyelinase activation domain 
neutral sphingomyelinase 
optical density 
phosphatidic acid 
polyacrylamid gel electrophoresis 
phosphate buffered saline 
phosphocholin e 
platelet-derived growth factor 
phosphoinositide 
phosphoinositide-3-kinase 
phosphatidyl-4.5-biphosphate 
protein kinase B 
protein kinase C 
phospholipase A2 
phospholipase C 
phospholipase D 
retinoblastoma 
Roswell Park Memorial Institute 
sphingosine-1-phosphate 
sphingolipid activator protein 
stress activated protein kinase 
sphingomyelin 
thin layer chromatography 
tumour necrosis factor a 
12-0-tetradecanoylphorbol-13-acetate 
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7.4  Deutsche Zusammenfassung 
7.4.1  EinfGhrung 
Dem deutschen Arzt Tudichum  gelang,  in  der zweiten  Halfte des  19.  Jahrhunderts  bei 
fraktionierenden  Kristallisationen  von  alkoholischen  Hirnextrakten  Verbindungen  zu 
isolieren,  die  neben Zucker und  Fettsauren  eine  organische  Base  enthielten.  Da  diese 
Base  ihm  riitselhaft erschien,  gab  er dieser Substanz in  Anlehnung  an  die griechische 
Sage VOn der Sphinx den Namen Sphingosin. 
Nach dieser Entdeckung  haben  Sphingolipide einen groBen Aufschwung  erlebt, da  sich 
herausstellte, dass Sphingolipide neben ihren Funktionen als Membranbausteine wichtige 
Eigenschaften  als  Signalmolekule  innerhalb  der  Zelle  offenbaren.  Ausgangspunkt  fUr 
diese  Entwicklung  war  die  Beobachtung,  dass  die  Proteinkinase  C  (PKC),  ein 
Signalmolekul,  welches  durch  den  Lipid-Botenstoff  Diacylglycerin  (DAG)  aktiviert wird, 
durch Sphingosin gehemmt wird. 
Ceramid,  eine  zentrale  Verbindung  innerhalb  der Klasse  der Sphingolipide,  wird  durch 
verschiedene Sphingomyelinasen freigesetzt und zusiitzlich auch  im Zuge einer de  noVO 
Synthese von  Sphingolipid  en,  bzw.  beim  Iysosomalen Abbau  glykosilierter Sphingolipide 
produziert.  Da  Sphingomyelin  jedoch  in  groBen  Mengen  in  der  Plasmamembran 
vorkommt,  und  nur ein  Schritt zur Bildung  VOn  Ceramid  netig ist,  geht man davon aus, 
dass vor allem die Sphingomyelinasen fUr eine schnelle Ceramid-Freisetzung im Rahmen 
von Signaltransduktions-Prozessen VOn  Bedeutung sind.  Die Signalmolekule Sphingosin 
und Sphingosin-1-Phosphat (S1 P) werden aus Ceramid durch Ceramidasen gebildet und 
scheinen  im  Gegensatz zu  Ceramid,  das vorwiegend zum Stop des Zell-Zyklus und  zur 
Apoptose  fUhrt,  vor allem  an  den  Prozessen  der Zell-Aktivierung  wie  Mitogenese  und 
Proliferation beteiligt zu sein. 
Ceramid als zentrales Signalmolekul wurde umfangreich charakterisiert. Nach Stimulation 
von Zellen mit entzundlichen Zytokinen wie  Interleukin  1~ (IL-1~), Tumornekrosefaktor a 
(TN Fa)  und  Interferon  'Y,  oder  Stressfaktoren  wie  UV-Strahlung,  Rentgenstrahlung, 
Hitzeschock oder oxidativem Stress kommt es zur Aktivierung von sauren und neutralen 
Sphingomyelinasen,  die  Sphingomyelin  in  Zellmembranen  zu  Ceramid  spalten.  Die 
Regulation  von  Sphingomyelinasen  liefern  aber  nur  einen  Teilaspekt,  die  Bildung  von 
Ceramid,  fUr das molekulare Verstiindnis des Ceramid-Stoffwechsels in  der Zelle.  Einen 
eben so  wichtig~n Beitrag liefern die den Abbau regulierenden Enzyme, die Ceramidasen. 
Ceramidasen  sind  Enzyme,  welche  in  der Lage  sind,  Ceramide  in  Sphingosin und  freie 
Fettsaure  zu  spalten.  Sphingosin  kann  dann  in  der  Foige  zu  Sphingosin-1-phosphat 
phosphoryliert werden. Sphingosin-1-phosphat ist als ein Mitogen und damit Ferderer von 
Wachstum in verschiedenen Zelltypen beschrieben. 
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Sphingosin entsteht nicht Ober de novo Synthese, so dass die Ceramidase-Aktivitiit nicht 
nur fOr  den Abbau  von  Ceramid wichtig  ist,  sondern  auch  fOr  das Entstehen relevanter 
Sphingosin- und  Sphingosin-1-phosphat-Spiegel  verantwortlich  ist.  Entsprechend  der 
assoziierten  Zellantworten  auf  Ceramide  bzw.  Sphingosin-1-phosphat  stellen  die 
Ceramidasen  SchlOsselenzyme  in  der  zelluliiren  Regulation  der  Balance  zwischen 
programmiertem Zelltod und Oberleben dar. 
Ceramidasen  werden  abhiingig  von  ihrem  pH-Optimum  in  drei  Klassen  unterteilt:  man 
unterscheidet  saure,  neutrale  und  alkalische  Ceramidasen.  Diese  Einteilung  basiert 
jedoch nicht ausschlieBlich auf dem entsprechenden pH-Optimum, sondern grOndet sich 
zusiitzlich auf Unterschiede in der genetischen Information. 
Bis heute ist Ober die Regulation und die Beteiligung der Ceramidasen an der zelluliiren 
SignalObertragung nur sehr wenig bekannt. 
Ziel dieser Arbeit ist es,  diese Rolle der Ceramidasen und  im  Besonderen der neutralen 
Ceramidase in der zelluliiren SignalObertragung zu erforschen, vornehmlich die Rolle bei 
zelluliirem Stress und Entzundungen. Weiterhin gilt es, die Effekte auf die Elimination von 
Ceramid  und  die  Produktion  von  Spingosin-1-phosphat  zu  erforschen,  urn  damit  die 
Konsequenzen  fOr  das  Gleichgewicht zwischen  programmiertem  Zelltod  auf der einen 
Seite und Wachstum und Oberleben auf der anderen Seite aufzudecken. 
7.4.2  Ergebnisse 
Der Lipid-Botenstoff Ceramid wird gebildet durch saure und  neutrale Sphingomyelinasen 
und abgebaut durch saure,  neutrale und  alkalische Ceramidasen. Kurzzeit-Stimulationen 
von  Mesangiumzellen mit dem pro-entzOndlichen Zytokin Interleukin  1~ (IL-1~) fOhren zu 
einem schnell en und  vorObergehenden Anstieg der neutralen Sphingomyelinase-Aktivitiit. 
1m  ersten  Teil  dieser  Arbeit  wird  Ober  einen  zweiten  verzogerten  Anstieg  der 
Sphingomyelinase-Aktivitiit innerhalb von Stunden nach Gabe von  IL-1~ berichtet. Parallel 
dazu  wird  ein Anstieg der Ceramidase-Aktivitiiten beobachtet,  was  dazu fOhrt,  dass die 
Ceramid-Spiegel innerhalb der Zelle nach Langzeit-Stimulation mit  IL-1~ relativ konstant 
bleiben. 
Der  Anstieg  der  neutralen  Ceramidase-Aktivitiit  erfolgt  aufgrund  einer  expressionalen 
Hochregulation,  welche  sich  sowohl  durch  erhohte  entsprechende  Ribonukleinsiiure-
Spiegel  als  auch  durch  eine  verstiirkte  Neusynthese  des  Proteins  zeigen.  Der 
beobachtete  Anstieg  von  neutraler Ceramidase kann  unter Costimulation  mit dem  p38-
Mitogen-aktivierten-Protein-Kinase  (MAPK)-Inhibitor SB  202190  dosisabhiingig  blockiert 
werden.  Dazu  passend  fOhrt  diese  Costimulation  zu  einem  Anstieg  der  Ceramid-
Formation.  Mesangiumzellen,  die  von  Miiusen  isoliert wurden,  denen  das  Gen  fOr  die 
MAPK-aktivierte-Protein-Kinase-2  fehlt,  reagieren  vergleichbar  auf  die  beschriebenen 
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Stimuli,  was  darauf  schliel1en  lasst,  das  die  MAPK-aktivierte-Protein-Kinase-2  als 
mogliches Target der p38-MAPK nicht in der Aktivierung der neutralen Ceramidase durch 
IL-1 ~ involviert ist. 
Daher  sprechen  die  Resultate  fOr  eine  biphasische  Regulation  der  Sphingomyelin-
Spaltung und eine verzogerte Ceramidase-Aktivierung nach einer Stimulation mit IL-1~. 
Ceramid-Spiegel  werden  stark erhoht durch  eine  Stimulation  von  Mesangiumzellen  mit 
dem  physiologischen  Botenstoff  Stickstoffmonoxid  (NO).  Dieser  Effekt  ist  durch  eine 
Aktivierung der Sphingomyelinase-Aktivitat und  eine Hemmung der Ceramidase-Aktivitat 
durch  NO  bedingt.  In  dem  zweiten  Teil  dieser  Arbeit  wird  beschrieben,  dass  diese 
Regulation  der  neutralen  Ceramidase  mit  einer  Reduzierung  der  Proteinmenge  der 
neutralen Ceramidase einhergeht. Diese NO-vermittelte Reduzierung der Aktivitat und der 
Proteinspiegel  wird  aufgehoben  durch  eine  zeitgleiche  Stimulation  mit  Stoffen,  die  zu 
einer Aktivierung der Proteinkinase C (PKC) fOhren,  wie zum  Beispiel Phorbolester oder 
die bekannten physiologischen Stimuli wie Angiotensin II und Adenosintriphosphat. 
Phosphorylierungs-Experimente ergaben, dass durch diese PKC-Aktivatoren die neutrale 
Ceramidase  direkt,  wahrscheinlich  durch  eines  der  in  Mesangiumzellen  bekannten 
Enzyme aus der PKC-Familie, phosphoryliert wird. Weitere Studien mit selektiven PKC-
Inhibitoren und rekombinaten PKC-Isoformen lassen den Schluss zu, dass wahrscheinlich 
die Isoform PKC-3 das entscheidende Enzym ist, welches die neutrale Ceramidase durch 
direkte Phosphorylierung davor schOtzt, durch NO abgebaut zu werden. Damit ergibt sich 
eine Moglichkeit, aktiv in die Stabilitat der neutralen Ceramidase und infolgedessen auch 
in die Ceramid-Spiegel der Zelle einzugreifen. 
Das  dritte  Kapitel  dieser Arbeit  beschreibt,  dass  der  im  zweiten  Teil  angefOhrte  NO-
vermittelte  Abbau  der  neutralen  Ceramidase  durch  eine  Aktivierung  des 
Ubiquitin/Proteasomen-Systems  bedingt  ist.  Durch  den  spezifischen  Proteasomen-
Inhibitor  Lactacystin  kann  der  Abbau  der  neutralen  Ceramidase  vollstandig  wieder 
aufgehoben werden. Dazu passend wird gezeigt, dass der zellulare Ceramid-Spiegel, der 
nach  NO-Stimulation  dramatisch  erhOht  ist,  durch  eine  zusatzliche  Stimulation  mit 
Lactacystin  wieder  reduziert  wird.  Durch  diesen  Mechanismus  ergibt  sich  ein  weitere 
Moglichkeit, in den Ceramid-Stoffwechsel regulierend einzugreifen. 
Der letzte Teil der Experimente befasst sich mit der zellularen Lokalisation der neutralen 
Ceramidase.  Durch  Herstellung  eines  Fusionsproteins  bestehend  aus  der  neutralen 
Ceramidase  und  einem  grOn  fluoreszierenden  Protein  (GFP),  welches  speziell  fOr 
derartige  Lokalisationsexperimente  verwendet  wird,  wird  in  Transfektions-Experimenten 
demonstriert, dass die neutrale Ceramidase in  weiten Teilen des Zytoplasma vorkommt. 
Eine  Doppelfarbung  mit  verschiedenen  organelltypischen  Antikorpern  lasst  darauf 
schliel1en,  dass  die  neutrale  Ceramidase  im  Zytoplasma  vorhanden  ist.  Durch  PKC-Supplement 
Aktivierung  kommt  es  zu  einer  Translokation  der  neutralen  Ceramidase  an  die 
Kernmembran. Die Bedeutung dieser Translokation ist noch ungewiss. 
7.4.3  Diskussion 
1m  Zuge der breiten  Dokumentation,  die  Ceramid  in  vielen  verschiedenen Zelltypen als 
pro-apoptotische Verbindung  beschreibt, wachst mehr und  mehr auch  das  Interesse an 
den am Ceramid-Stoffwechsel beteiligten Enzymen. 
Wie schon ausgefOhrt,  legt diese Arbeit den Schwerpunkt auf die Regulation der Klasse 
der Ceramidasen und damit auf die Schl(jsselenzyme der Ceramid-Spaltung. 
Die  beschriebenen  Regulationen,  insbesondere  der  neutralen  Ceramidase,  durch  pro-
inflammatorische  Zylokine  wie  Interleukin  1~  oder  Tumornekrosefaktor  ex  und 
Stickstoffmonoxid  zeigen  einen  moglichen  Zusammenhang  zwischen  pathologischen 
Prozessen und dem Sphingolipid-Stoffwechsel. 
Die  Storung  der Apoptose,  des  programmierten  Zelltodes,  als  ein  wichtiges  zellulares 
Instrument,  urn  Proliferation  zu  begrenzen,  ist bei  der Pathogenese vieler Krankheiten, 
insbesondere bei der Krebsentstehung beteiligt. 
Durch eine mogliche Regulation der Ceramid-Spiegel innerhalb der Zelle kann so gezielt 
auf apoptotische Prozesse Einfluss genommen werden,  beziehungsweise diese konnen 
ausgelost werden.  Eine  Ceramid-Abbau  durch  Ceramidasen  hat zudem  eine  ErhOhung 
der  Foigeprodukte  Sphingosin  und  Sphingosin-1-phosphat  zur  Foige.  Besonders 
Sphingosin-1-phosphat ist in  vielen  Zellsystemen  als  Mitogen und  Wachstums-Forderer 
beschrieben worden. Zudem wird es nicht auf dem de novo Syntheseweg produziert, was 
die  Bedeutung der Ceramidasen als  Enzym,  welches fOr  die  Produktion von  Sphingosin 
bzw.  Sphingosin-1-phosphat mit verantwortlich ist,  noch weiter erhoht.  Damit stellen die 
Ceramidasen  als  Enzyme,  die  das  Ceramid/Sphingosin/Sphingosin-1-phosphat-
Gleichgewicht  maBgeblich  beeinflussen,  wichtige  potentielle  Ziele  f(jr  eine 
Arzneistofftherapie dar. Durch Hemmung oder Abbau der Ceramidasen kann es zu einer 
Ceramid-Akkumulation  kommen,  wahrend  eine  Induktion  oder  Aktivierung  zu  einer 
Verringerung der Ceramid-Spiegel und einer Erhohung der Sphingosin- und Sphingosin-
1-phosphat-Spiegel fOhrt. 
Einige  klinische  Studien  beschreiben  schon  Erfolge  einer  Therapie,  die  in  die 
Ceramidase-Regulation  bzw.  in  das  Ceramid/Sphingosin-1-phosphat-Gleichgewicht 
eingreifen. 
Humane  Kolon-Karzinom-Zellen  zeigen  eine  50%ige  Abnahme  des  zellularen  Cera mid-
Gehaltes  verglichen  mit  gesunder  Darm-Mucosa.  Die  Behandlung  mit  einem  potenten 
Hemmstoff der Ceramidase (B13)  erhoht hier den  Ceramid-Spiegel in  den Tumorzellen, 
was zu  einer maximalen Aktivierung der apoptotischen Kaskade f(jhrt, wahrend gesunde 
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Zellen nicht wesentlich beeinflusst werden.  Damit stellt diese Ceramidase-Inhibition eine 
vielversprechende Strategie dar, Tumorzellen selektiv zu eliminieren. 
Weiterhin  wird  gezeigt,  dass  von  auBen  appliziertes  Ceramid  die  Wirkungen  einer 
bestehenden Krebs-Therapie noch zu erhohen vermag. 
Auch  ein  Therapieansatz zur Pravention  einer erhOhten  Sphingosin-1-phosphat-Bildung 
mit einem  Inhibitor der Sphingosin-1-kinase kombiniert mit  einer Forderung der Ceramid 
de  novo  Synthese  zeigt  synergistische  Effekte  bezuglich  der  Zelltoxizitat.  Die 
beschriebene Therapie mit Safingol (Sphingosin-Kinase-Inhibitor) und Fenretinide (erhOht 
die  Ceramid  de  novo  Synthese)  wird  bereits  in  klinischen  Phase  II  Studien  bei 
verschiedenen Krebsformen getestet. 
Bezogen  auf die  Ergebnisse dieser Arbeit ergeben  sich  vielfaltige  Moglichkeiten  in  die 
Regulation der neutralen Ceramidase einzugreifen.  Es  konnte gezeigt werden,  dass die 
neutrale Ceramidase sowohl auf Ebene der Genexpression (transkriptionelle Regulation) 
als  auch  auf  Ebene  der  Proteinexpression  (translationale  Regulation)  reguliert  wird. 
Weiterhin  zeigen  sich  verschiedene  post-translationale  Regulationsmechanismen  wie 
Phosphorylierung,  Ubiquitinierung  oder  Translokation.  All  diese  Mechanismen  tragen 
dazu  bei,  die Ceramid-Spiegel innerhalb der Zelle zu  regulieren,  und  damit das weitere 
Schicksal der Zelle zu bestimmen. 
Zukunftige Arbeiten werden zeigen, ob die neutrale Ceramidase als ein mogliches Target 
fUr  die  Entwicklung  neuer Therapie-Strategien  im  Kampf gegen  Entzundung und  Krebs 
erfolgreich angegangen werden kann. 
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